ATR-X-Related Syndrome

Mendelian MONDO:0016980 Pathograph 24 Show in embeddings browser Genetic Disease Nervous System Disease

ATR-X-related syndrome is an X-linked neurodevelopmental spectrum caused by pathogenic germline variants that impair the ATRX chromatin remodeler. Affected individuals can have developmental delay or intellectual disability, hypotonia, a characteristic facial appearance, genital anomalies, gastrointestinal and skeletal manifestations, seizures, and variably alpha-thalassemia. The historical alpha-thalassemia X-linked intellectual disability and intellectual disability-hypotonic facies labels overlap clinically and mechanistically; they are represented here as nosologic subtypes rather than independent mechanism records.

Ask OpenScientist

Ask a research question about ATR-X-Related Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
6
Pathophys.
17
Phenotypes
3
Hypotheses
2
Gaps
24
Pathograph
1
Genes
3
Medical Actions
2
Subtypes
12
References
1
Deep Research
👪

Inheritance

1
X-linked inheritance HP:0001417
ATR-X-related syndrome is inherited in an X-linked manner. A pathogenic variant may be inherited from a heterozygous mother or arise de novo.
X-linked inheritance
Show evidence (3 references)
PMID:20301622 SUPPORT Human Clinical
"ATR-X syndrome is inherited in an X-linked manner."
GeneReviews supports the broad X-linked mode used at the umbrella level.
PMID:20301622 SUPPORT Human Clinical
"mother of a proband may be heterozygous (i.e., a carrier) or the affected"
GeneReviews supports maternal heterozygosity and transmission.
PMID:20301622 SUPPORT Human Clinical
"individual may have a de novo pathogenic variant."
GeneReviews also documents de novo occurrence.
◆

Subtypes

2
Alpha-Thalassemia X-Linked Intellectual Disability Syndrome MONDO:0010519
Curation interpretation: this is the conventional ATR-X label associated with alpha-thalassemia or HbH inclusions. Alpha-thalassemia is variable rather than required, so this child is represented as a historical clinical label within the shared ATRX spectrum, not as a separate molecular mechanism.
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"Alpha-thalassemia X-linked intellectual disability (ATR-X) syndrome is characterized by distinctive craniofacial features, genital anomalies, hypotonia, and mild-to-profound developmental delay / intellectual disability (DD/ID)."
GeneReviews provides the established clinical identity for the alpha-thalassemia-associated label.
Intellectual Disability-Hypotonic Facies Syndrome, X-Linked 1 MONDO:0010663
Curation interpretation: because MRXHF1 and ATR-X share the causal gene and numerous reported manifestations, this record represents MRXHF1 as an overlapping historical or nosologic child within the ATR-X-related spectrum, not as a mutually exclusive HbH-negative biological subtype.
Show evidence (2 references)
PMID:39363269 SUPPORT Human Clinical
"X-linked intellectual disability-hypotonic facies syndrome-1 (MRXHF1) and Alpha-thalassemia X-linked intellectual disability (ATR-X) syndrome are caused by pathogenic variant in the ATRX gene"
The report explicitly identifies both labels as ATRX-associated and describes a shared broad clinical spectrum.
PMID:39363269 SUPPORT Human Clinical
"Syndromes caused by ATRX germline mutation share"
The review documents substantial phenotypic overlap across syndromes caused by germline ATRX variants.
◈

Mechanistic Hypotheses

3
ATRX Chromatin and Transcriptional Dysregulation
atrx_chromatin_dysregulation CANONICAL
Evidence balance 3 support
Impaired ATRX chromatin-remodeling activity disrupts ATRX-DAXX-dependent heterochromatin regulation and tandem-repeat-associated gene expression, producing a multisystem developmental disorder.
Pathograph links
ATRX Chromatin-Remodeling Dysfunction -> ATRX-DAXX Heterochromatin Remodeling Impairment DIRECT Impaired ATRX function disrupts its DAXX-associated chromatin-remodeling activity at heterochromatin.
ATRX Chromatin-Remodeling Dysfunction -> Tandem-Repeat-Associated Gene Dysregulation DIRECT ATRX impairment disrupts binding and transcriptional regulation at tandem-repeat-associated loci.
ATRX Chromatin-Remodeling Dysfunction -> Multisystem Developmental and Clinical Consequences INDIRECT UNKNOWN INTERMEDIATES The broad human phenotype follows ATRX dysfunction through incompletely resolved tissue- and locus-specific intermediates.
Tandem-Repeat-Associated Gene Dysregulation -> Alpha-Thalassemia with HbH Hemoglobin INDIRECT UNKNOWN INTERMEDIATES Repeat-associated transcriptional dysregulation includes reduced alpha-globin expression and provides a mechanistic link to HbH.
Show evidence (3 references)
PMID:7697714 SUPPORT Human Clinical
"The complex ATR-X phenotype suggests that XH2, when mutated, down-regulates expression of several genes, including the alpha-globin genes, indicating that it could be a global transcriptional regulator."
The foundational report supports broad transcriptional dysregulation as the canonical disease model.
PMID:12953102 SUPPORT In Vitro
"ATRX and Daxx are components of an ATP-dependent chromatin-remodeling"
Biochemical evidence supports the ATRX-DAXX chromatin-remodeling arm of the canonical model.
PMID:21029860 SUPPORT In Vitro
"Genes associated with these TRs can be dysregulated when ATRX is"
The study supports tandem-repeat-associated transcriptional dysregulation in the canonical model.
Sertoli Cell and Androgen-Signaling Model
atrx_sertoli_androgen_model EMERGING
Evidence balance 1 support
Mouse Sertoli-cell loss of Atrx causes proliferative arrest and apoptosis and perturbs androgen-receptor-dependent transcription. This is a candidate explanation for human genital anomalies, not an established direct human causal chain.
Pathograph links
ATRX Chromatin-Remodeling Dysfunction -> Sertoli Cell Survival and Androgen-Signaling Impairment DIRECT This emerging branch captures the tissue-specific consequence observed after Atrx loss in mouse Sertoli cells.
Sertoli Cell Survival and Androgen-Signaling Impairment -> Genital Anomalies INDIRECT UNKNOWN INTERMEDIATES The mouse Sertoli/androgen findings are a candidate, not proven, route to the broad human genital-anomaly spectrum.
Sertoli Cell Survival and Androgen-Signaling Impairment -> Hypospadias INDIRECT UNKNOWN INTERMEDIATES Altered Sertoli-cell survival and androgen-dependent transcription are an emerging candidate pathway to hypospadias.
Sertoli Cell Survival and Androgen-Signaling Impairment -> Cryptorchidism INDIRECT UNKNOWN INTERMEDIATES Altered Sertoli-cell survival and androgen-dependent transcription are an emerging candidate pathway to cryptorchidism.
Show evidence (1 reference)
PMID:21427128 SUPPORT Model Organism
"ScAtrxKO mice developed small testes and discontinuous tubules, due to prolonged G2/M phase and apoptosis of proliferating Sertoli cells during fetal life."
The conditional mouse model supports this emerging hypothesis.
Oligodendrocyte and Myelination Model
atrx_glial_myelination_model EMERGING
Evidence balance 1 support
Mouse ATRX loss impairs oligodendrocyte-progenitor differentiation and myelination. The extent to which this model explains human white-matter abnormalities remains unresolved.
Pathograph links
ATRX Chromatin-Remodeling Dysfunction -> Oligodendrocyte Differentiation and Myelination Impairment INDIRECT KNOWN INTERMEDIATES In mice, ATRX loss affects myelination through systemic thyroid-hormone effects and OPC-intrinsic differentiation, so this emerging branch has known intervening routes rather than a single direct link.
Show evidence (1 reference)
PMID:37925436 SUPPORT Model Organism
"These functions of ATRX identified in mice could explain white matter pathogenesis observed in ATR-X syndrome patients."
The authors explicitly frame the mouse-to-human link as provisional.
?

Discussions and Knowledge Gaps

2
To what extent do Sertoli-cell and oligodendrocyte phenotypes in conditional Atrx mouse models explain genital and white-matter manifestations in human ATR-X-related syndrome?
HUMAN MODEL MISMATCH OPEN gap_atrx_mouse_tissue_models_human_translation
Attached to
pathophysiology#Sertoli Cell Survival and Androgen-Signaling Impairment pathophysiology#Oligodendrocyte Differentiation and Myelination Impairment
Conditional mouse studies provide tissue-specific mechanisms, but neither branch has been established as the causal route in human tissue. The glial study explicitly says the mouse functions could explain human white-matter pathology, and the Sertoli model does not directly reproduce or prove each human genital phenotype. Human cellular models and patient-correlated molecular readouts are needed before these branches are considered canonical.
Show evidence (1 reference)
PMID:37925436 SUPPORT Model Organism
"These functions of ATRX identified in mice could explain white matter pathogenesis observed in ATR-X syndrome patients."
The authors explicitly qualify translation from mouse to human.
Does germline ATRX dysfunction confer a clinically meaningful osteosarcoma or broader tumor predisposition, and through which mechanism?
KNOWLEDGE GAP OPEN gap_atrx_osteosarcoma_tumor_predisposition
Attached to
pathophysiology#ATRX-DAXX Heterochromatin Remodeling Impairment
GeneReviews reports osteosarcoma in only a few males with germline ATRX variants. The evidence is insufficient to assert a tumor-predisposition phenotype or surveillance recommendation, and a mechanistic link to heterochromatin or telomere dysfunction remains unestablished.
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"Osteosarcoma has been reported in a few males with germline pathogenic variants."
The rare reports motivate the gap without establishing predisposition.
⚙

Pathophysiology

6
ATRX Chromatin-Remodeling Dysfunction
Pathogenic constitutional ATRX variants impair an ATP-dependent chromatin remodeler of the SWI/SNF family. Clinically observed alleles are often described as hypomorphic; this node therefore models impaired ATRX function without asserting that every patient allele is a complete null. The defect alters chromatin targeting or remodeling and dysregulates transcription across multiple genomic contexts.
ATRX Chromatin and Transcriptional Dysregulation Oligodendrocyte and Myelination Model Sertoli Cell and Androgen-Signaling Model
ATRX hgnc:886 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves ATRX (hgnc:886). hgnc:886 is a gene from the HUGO Gene Nomenclature Committee.
chromatin remodeling GO:0006338 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased chromatin remodeling (GO:0006338). GO:0006338 is a biological process from the Gene Ontology. ↓ DECREASED regulation of DNA-templated transcription GO:0006355 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal regulation of DNA-templated transcription (GO:0006355). GO:0006355 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
ATRX-DAXX Heterochromatin Remodeling Impairment Impaired ATRX function disrupts its DAXX-associated chromatin-remodeling activity at heterochromatin. ATRX Chromatin and Transcriptional Dysregulation
Tandem-Repeat-Associated Gene Dysregulation ATRX impairment disrupts binding and transcriptional regulation at tandem-repeat-associated loci. ATRX Chromatin and Transcriptional Dysregulation
Sertoli Cell Survival and Androgen-Signaling Impairment This emerging branch captures the tissue-specific consequence observed after Atrx loss in mouse Sertoli cells. Sertoli Cell and Androgen-Signaling Model
Oligodendrocyte Differentiation and Myelination Impairment In mice, ATRX loss affects myelination through systemic thyroid-hormone effects and OPC-intrinsic differentiation, so this emerging branch has known intervening routes rather than a single direct link. Oligodendrocyte and Myelination Model
Multisystem Developmental and Clinical Consequences The broad human phenotype follows ATRX dysfunction through incompletely resolved tissue- and locus-specific intermediates. ATRX Chromatin and Transcriptional Dysregulation
Show evidence (4 references)
PMID:36292677 SUPPORT Human Clinical
"ATR-X syndrome is a rare X-linked congenital disorder caused by hypomorphic mutations in the ATRX gene."
The clinical cohort supports pathogenic hypomorphic ATRX impairment as the initiating lesion.
PMID:7697714 SUPPORT Human Clinical
"The complex ATR-X phenotype suggests that XH2, when mutated, down-regulates expression of several genes, including the alpha-globin genes, indicating that it could be a global transcriptional regulator."
The foundational report links ATRX mutation to broad transcriptional dysregulation, including alpha-globin downregulation.
PMID:12953102 SUPPORT In Vitro
"ATRX and Daxx are components of an ATP-dependent chromatin-remodeling"
The biochemical study directly supports the ATP-dependent chromatin-remodeling description.
+ 1 more reference
ATRX-DAXX Heterochromatin Remodeling Impairment
ATRX cooperates with DAXX in a chromatin-remodeling and histone-chaperone complex. The prevailing model places H3.3 at heterochromatin to help maintain H3K9me3-associated silencing. ATR-X blood samples also show a specific methylation signature enriched near pericentromeric and telomeric regions, consistent with disturbed heterochromatin regulation.
heterochromatin organization GO:0070828 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal heterochromatin organization (GO:0070828). GO:0070828 is a biological process from the Gene Ontology. ⚠ ABNORMAL nucleosome assembly GO:0006334 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal nucleosome assembly (GO:0006334). GO:0006334 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Show evidence (3 references)
PMID:12953102 SUPPORT In Vitro
"Taken together, the results suggest that ATRX functions in conjunction with Daxx in a novel chromatin-remodeling complex. The defects in ATRX syndrome may result from inappropriate expression of genes controlled by this complex."
The study establishes the ATRX-DAXX complex and its proposed disease relevance.
PMID:26773061 SUPPORT Other
"We provide an overview of the individual components (ATRX, DAXX and/or H3.3) tested in each study and propose a model where the ATRX/DAXX chaperone complex deposits H3.3 to maintain the H3K9me3 modification at heterochromatin throughout the genome."
This mechanistic review supports the H3.3-deposition and H3K9me3 maintenance model.
PMID:28293299 SUPPORT Human Clinical
"differentially methylated regions showed evidence of preferential clustering in pericentromeric and telometric chromosomal regions, areas where ATRX has multiple functions related to maintenance of heterochromatin and genomic integrity"
The human blood methylation signature is consistent with disturbance at ATRX-associated heterochromatic regions.
Tandem-Repeat-Associated Gene Dysregulation
ATRX binds G-rich tandem-repeat sequences in telomeres and euchromatin, including sequences capable of forming non-B DNA structures. ATRX mutation can produce repeat-size-dependent dysregulation and skewed allelic expression at associated genes, including downregulation of alpha-globin.
ATRX Chromatin and Transcriptional Dysregulation
regulation of DNA-templated transcription GO:0006355 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal regulation of DNA-templated transcription (GO:0006355). GO:0006355 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Alpha-Thalassemia with HbH Hemoglobin Repeat-associated transcriptional dysregulation includes reduced alpha-globin expression and provides a mechanistic link to HbH. ATRX Chromatin and Transcriptional Dysregulation
Show evidence (2 references)
PMID:21029860 SUPPORT In Vitro
"Here we show that ATRX binds to tandem repeat (TR) sequences in both telomeres and euchromatin. Genes associated with these TRs can be dysregulated when ATRX is mutated, and the change in expression is determined by the size of the TR, producing skewed allelic expression."
The study demonstrates the repeat-binding and allele-specific expression mechanism.
PMID:21029860 SUPPORT In Vitro
"Many of the TRs are G rich and predicted to form non-B DNA structures (including G-quadruplex) in vivo. We show that ATRX binds G-quadruplex structures in vitro"
The experiments support binding to G-rich repeat structures as a molecular basis for the repeat-associated effect.
Sertoli Cell Survival and Androgen-Signaling Impairment
In a Sertoli-cell-specific Atrx knockout mouse, proliferating Sertoli cells show prolonged G2/M and apoptosis. ATRX also physically interacts with the androgen receptor and promotes expression of androgen-dependent genes. These observations form an emerging model for human genital anomalies.
Sertoli Cell and Androgen-Signaling Model
Sertoli cell CL:0000216 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Sertoli cell (CL:0000216). CL:0000216 is a cell type from the Cell Ontology.
regulation of DNA-templated transcription GO:0006355 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal regulation of DNA-templated transcription (GO:0006355). GO:0006355 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Genital Anomalies The mouse Sertoli/androgen findings are a candidate, not proven, route to the broad human genital-anomaly spectrum. Sertoli Cell and Androgen-Signaling Model
Hypospadias Altered Sertoli-cell survival and androgen-dependent transcription are an emerging candidate pathway to hypospadias. Sertoli Cell and Androgen-Signaling Model
Cryptorchidism Altered Sertoli-cell survival and androgen-dependent transcription are an emerging candidate pathway to cryptorchidism. Sertoli Cell and Androgen-Signaling Model
Show evidence (2 references)
PMID:21427128 SUPPORT Model Organism
"ScAtrxKO mice developed small testes and discontinuous tubules, due to prolonged G2/M phase and apoptosis of proliferating Sertoli cells during fetal life."
Conditional mouse deletion demonstrates defective fetal Sertoli-cell survival.
PMID:21427128 SUPPORT Model Organism
"These data suggest that ATRX can directly enhance the expression of androgen-dependent genes through physical interaction with AR."
Mouse and Sertoli-cell experiments support an ATRX-androgen-receptor transcriptional interaction.
Oligodendrocyte Differentiation and Myelination Impairment
Mouse ATRX loss causes myelination deficits and impairs oligodendrocyte progenitor differentiation, favoring astrocytic differentiation. The study proposes that these functions could explain white-matter pathology in people with ATR-X syndrome; human causal validation remains needed.
oligodendrocyte precursor cell CL:0002453 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves oligodendrocyte precursor cell (CL:0002453). CL:0002453 is a cell type from the Cell Ontology. oligodendrocyte CL:0000128 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves oligodendrocyte (CL:0000128). CL:0000128 is a cell type from the Cell Ontology.
oligodendrocyte differentiation GO:0048709 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased oligodendrocyte differentiation (GO:0048709). GO:0048709 is a biological process from the Gene Ontology. ↓ DECREASED myelination GO:0042552 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased myelination (GO:0042552). GO:0042552 is a biological process from the Gene Ontology. ↓ DECREASED
Show evidence (2 references)
PMID:37925436 SUPPORT Model Organism
"We show that loss of ATRX leads to myelination deficits in male mice that are partially rectified upon systemic thyroxine administration."
The mouse experiment establishes an ATRX-dependent myelination deficit; it does not justify thyroxine as a human treatment.
PMID:37925436 SUPPORT Model Organism
"Targeted ATRX inactivation in either neurons or oligodendrocyte progenitor cells (OPCs) reveals OPC-intrinsic effects on myelination."
Targeted mouse experiments support an OPC-intrinsic contribution to the myelination phenotype.
Multisystem Developmental and Clinical Consequences
Human ATR-X-related syndrome has a recognizable multisystem phenotype. This consequence node connects the clinically observed manifestations while explicitly leaving the molecular and tissue-specific intermediates unresolved; it does not imply that the upstream chromatin defect directly causes each feature in one step.
Downstream
Intellectual Disability
Global Developmental Delay
Hypotonia
Distinctive Craniofacial Features
Microcephaly
Telecanthus
Everted Lower Lip
Genital Anomalies
Hypospadias
Cryptorchidism
Alpha-Thalassemia with HbH Hemoglobin
Seizures
Feeding Difficulties
Drooling
Constipation
Gastroesophageal Reflux
Skeletal Anomalies
Show evidence (2 references)
PMID:20301622 SUPPORT Human Clinical
"Alpha-thalassemia X-linked intellectual disability (ATR-X) syndrome is characterized by distinctive craniofacial features, genital anomalies, hypotonia, and mild-to-profound developmental delay / intellectual disability (DD/ID)."
GeneReviews establishes the core multisystem clinical presentation.
PMID:36292677 SUPPORT Human Clinical
"A typical phenotype is well defined, with cognitive impairment, characteristic facial dysmorphism, hypotonia, gastrointestinal, skeletal, urogenital, and hematological anomalies as characteristic features."
The cohort supports the broader gastrointestinal, skeletal, urogenital, and hematologic spectrum.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for ATR-X-Related Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

17
Digestive 3
Feeding Difficulties HP:0011968 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Feeding difficulties (HP:0011968). HP:0011968 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"gastrointestinal manifestations and feeding difficulties, excessive drooling"
GeneReviews documents feeding difficulties.
Constipation HP:0002019 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Constipation (HP:0002019). HP:0002019 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39741769 SUPPORT Human Clinical
"significant gastrointestinal (GI) complications, such as abdominal distension, chronic constipation, feeding difficulties, gastroesophageal reflux"
The clinical report explicitly documents chronic constipation.
Gastroesophageal Reflux HP:0002020 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Gastroesophageal reflux (HP:0002020). HP:0002020 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39741769 SUPPORT Human Clinical
"significant gastrointestinal (GI) complications, such as abdominal distension, chronic constipation, feeding difficulties, gastroesophageal reflux"
The clinical report explicitly documents gastroesophageal reflux.
Genitourinary 2
Hypospadias HP:0000047 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypospadias (HP:0000047). HP:0000047 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"a range from hypospadias and undescended testicles, to severe hypospadias and ambiguous genitalia"
GeneReviews explicitly lists hypospadias.
Cryptorchidism HP:0000028 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cryptorchidism (HP:0000028). HP:0000028 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"a range from hypospadias and undescended testicles"
GeneReviews explicitly lists undescended testicles.
Head and Neck 3
Distinctive Craniofacial Features Abnormal facial shape HP:0001999 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal facial shape (HP:0001999). HP:0001999 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"Craniofacial abnormalities include small head circumference, telecanthus or widely spaced eyes, short triangular nose, tented upper lip, and thick or everted lower lip with coarsening of the facial features over time."
GeneReviews describes the characteristic craniofacial pattern.
Microcephaly HP:0000252 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Microcephaly (HP:0000252). HP:0000252 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"Craniofacial abnormalities include small head circumference"
GeneReviews documents small head circumference.
Drooling HP:0002307 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Drooling (HP:0002307). HP:0002307 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"feeding difficulties, excessive drooling, and genital anomalies are managed per standard of care"
GeneReviews documents excessive drooling.
Musculoskeletal 2
Hypotonia HP:0001252 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypotonia (HP:0001252). HP:0001252 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"is characterized by distinctive craniofacial features, genital anomalies, hypotonia, and mild-to-profound developmental delay"
GeneReviews lists hypotonia among the characterizing features.
Skeletal Anomalies Abnormality of the skeletal system HP:0000924 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormality of the skeletal system (HP:0000924). HP:0000924 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36292677 SUPPORT Human Clinical
"A typical phenotype is well defined, with cognitive impairment, characteristic facial dysmorphism, hypotonia, gastrointestinal, skeletal, urogenital, and hematological anomalies as characteristic features."
The cohort identifies skeletal anomalies as characteristic.
Nervous System 3
Intellectual Disability HP:0001249 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intellectual disability (HP:0001249). HP:0001249 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"Alpha-thalassemia X-linked intellectual disability (ATR-X) syndrome is characterized by distinctive craniofacial features, genital anomalies, hypotonia, and mild-to-profound developmental delay / intellectual disability (DD/ID)."
GeneReviews lists intellectual disability as a core feature.
Global Developmental Delay HP:0001263 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Global developmental delay (HP:0001263). HP:0001263 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"mild-to-profound developmental delay / intellectual disability (DD/ID)"
GeneReviews documents developmental delay in the syndrome.
Seizures HP:0001250 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Seizure (HP:0001250). HP:0001250 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"Treatment of manifestations: DD/ID, seizures, gastrointestinal manifestations and feeding difficulties, excessive drooling, and genital anomalies are managed per standard of care."
GeneReviews includes seizures among managed manifestations.
Other 4
Telecanthus HP:0000506 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Telecanthus (HP:0000506). HP:0000506 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"telecanthus or widely spaced eyes, short triangular nose, tented upper lip"
GeneReviews lists telecanthus among the facial features.
Everted Lower Lip Everted lower lip vermilion HP:0000232 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Everted lower lip vermilion (HP:0000232). HP:0000232 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"tented upper lip, and thick or everted lower lip with coarsening of the facial features over time"
GeneReviews describes the thick or everted lower lip.
Genital Anomalies Abnormal male external genitalia morphology HP:0000032 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal male external genitalia morphology (HP:0000032). HP:0000032 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"genital anomalies comprise a range from hypospadias and undescended testicles, to severe hypospadias and ambiguous genitalia, to normal-appearing female external genitalia"
GeneReviews describes the full genital-anomaly spectrum.
Alpha-Thalassemia with HbH Hemoglobin FREQUENT HP:0011903 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is HbH hemoglobin (HP:0011903). HP:0011903 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:20301622 SUPPORT Human Clinical
"Alpha-thalassemia, observed in about 75% of affected individuals, is mild and typically does not require treatment."
The approximately 75% estimate supports both the association and the FREQUENT band.
PMID:7697714 SUPPORT Human Clinical
"The ATR-X syndrome is an X-linked disorder comprising severe psychomotor retardation, characteristic facial features, genital abnormalities, and alpha-thalassemia."
The foundational clinical description includes alpha-thalassemia.
PMID:39363269 SUPPORT Human Clinical
"form beta tetramers (HbH)"
The review explicitly connects reduced alpha-globin expression to HbH tetramer formation.
🧬

Genetic Associations

1
ATRX Pathogenic Germline Variants
Gene: ATRX hgnc:886 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is ATRX (hgnc:886). hgnc:886 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (5 references)
PMID:20301622 SUPPORT Human Clinical
"The diagnosis of ATR-X syndrome is established in a proband with suggestive findings, a 46,XY karyotype, and a hemizygous pathogenic variant in ATRX identified by molecular genetic testing."
GeneReviews establishes hemizygous ATRX variants as causative.
PMID:36292677 SUPPORT Human Clinical
"ATR-X syndrome is a rare X-linked congenital disorder caused by hypomorphic mutations in the ATRX gene."
The cohort supports impaired or hypomorphic constitutional alleles.
PMID:36292677 SUPPORT Human Clinical
"specific ATRX protein domains are not well established and should not be used"
The cohort cautions against routine prognostic use of broad domain-specific genotype-phenotype correlations.
+ 2 more references
🗃️

External Assertions

1
ClinGen ATRX gene-disease validity assertion
ClinGen gene disease validity CGGV:assertion_5296ecdf-b709-47bd-9032-daec8b91e300-2021-09-28T220000.000Z
ClinGen classifies the X-linked ATRX–ATR-X-related syndrome relationship at the MONDO:0016980 umbrella as Definitive.
Show evidence (1 reference)
CGGV:assertion_5296ecdf-b709-47bd-9032-daec8b91e300-2021-09-28T220000.000Z SUPPORT Other
"ATRX | HGNC:886 | ATR-X-related syndrome | MONDO:0016980 | XL | Definitive"
The generated ClinGen record anchors the gene, umbrella disease identity, X-linked inheritance, and definitive classification.
💊

Medical Actions

3
Supportive and Phenotype-Directed Care
Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Management is supportive and individualized, including developmental and educational support and standard care for seizures, gastrointestinal and feeding problems, drooling, and genital anomalies.
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"Treatment of manifestations: DD/ID, seizures, gastrointestinal manifestations and feeding difficulties, excessive drooling, and genital anomalies are managed per standard of care."
GeneReviews supports manifestation-directed standard care.
Genetic Counseling and Family Testing
Action: Genetic CounselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Genetic Counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. NCIT:C15240
Counseling should address X-linked recurrence, carrier testing for at-risk females, and reproductive testing options once the familial ATRX variant is known.
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"Once the ATRX pathogenic variant in the family has been identified, carrier testing for at-risk females, prenatal testing for pregnancies at increased risk, and preimplantation genetic testing are possible."
GeneReviews supports counseling and family-based testing options.
Pyridostigmine for Severe Gastrointestinal Dysmotility
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: pyridostigmine CHEBI:8665 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses pyridostigmine (CHEBI:8665). CHEBI:8665 is a therapeutic agent from Chemical Entities of Biological Interest.
Pyridostigmine produced reported benefit in one child with ATR-X syndrome and gastrointestinal dysmotility. This is an off-label single-case observation with limited pediatric evidence, not established syndrome management.
Show evidence (2 references)
PMID:39741769 SUPPORT Human Clinical
"We report a patient with ATR-X syndrome suffering from gastrointestinal dysmotility and highlight the beneficial effects of pyridostigmine."
The publication reports benefit in a single ATR-X case.
PMID:39741769 SUPPORT Human Clinical
"Knowledge about the role and appropriate dosage of pyridostigmine in GI motility disorders is limited."
The same report explicitly limits confidence and dosing knowledge.
🔬

Diagnosis

2
Peripheral-Blood DNA Methylation Episignature
A highly specific blood DNA methylation episignature can support diagnosis in phenotypically complex cases or help interpret an ATRX variant of uncertain significance. It is supportive rather than a standalone replacement for clinical and sequence interpretation.
diagnostic procedure NCIT:C18020 NCI Thesaurus (NCIT)
Results: A matching ATR-X methylation episignature provides supportive molecular evidence.
Show evidence (1 reference)
PMID:28293299 SUPPORT Human Clinical
"Most significant methylation changes in the 14 genomic loci provide a unique epigenetic signature for this syndrome that may be used as a highly sensitive and specific diagnostic biomarker to support the diagnosis of ATR-X, particularly in patients with phenotypic complexity and in patients with..."
The study supports the episignature specifically as an adjunct in complex cases and for uncertain variants.
📊

Prevalence

1
Male newborns
Birth Prevalence 2.5–3.333333 per 100,000 1–9 per 100,000
The literature review reports an estimated birth prevalence of one in 30,000 to one in 40,000 male newborns.
Show evidence (1 reference)
PMID:39363269 SUPPORT Human Clinical
"estimated prevalence of 1/30,000–1/40,000 in male newborns"
The source explicitly reports the sex-specific newborn prevalence range; its reciprocal corresponds to 2.5–3.33 cases per 100,000 male births.
{ }

Source YAML

click to show 
name: ATR-X-Related Syndrome
creation_date: "2026-06-03T00:00:00Z"
description: >-
  ATR-X-related syndrome is an X-linked neurodevelopmental spectrum caused by
  pathogenic germline variants that impair the ATRX chromatin remodeler.
  Affected individuals can have developmental delay or intellectual
  disability, hypotonia, a characteristic facial appearance, genital
  anomalies, gastrointestinal and skeletal manifestations, seizures, and
  variably alpha-thalassemia. The historical alpha-thalassemia X-linked
  intellectual disability and intellectual disability-hypotonic facies labels
  overlap clinically and mechanistically; they are represented here as
  nosologic subtypes rather than independent mechanism records.
category: Mendelian
parents:
- Genetic Disease
- Nervous System Disease
disease_term:
  preferred_term: ATR-X-related syndrome
  term:
    id: MONDO:0016980
    label: ATR-X-related syndrome
notes: >-
  This umbrella record consolidates the two prior ATRX-associated records under
  their shared MONDO parent. MONDO:0010519 and MONDO:0010663 are retained as
  overlapping historical or nosologic children; the current evidence does not
  establish substantially independent mechanisms that would justify separate
  disease-mechanism files.
references:
- reference: PMID:20301622
  title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
  tags:
  - GeneReviews
- reference: PMID:7697714
  title: Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome).
- reference: PMID:12953102
  title: The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies.
- reference: PMID:21029860
  title: ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner.
- reference: PMID:21427128
  title: Defective survival of proliferating Sertoli cells and androgen receptor function in a mouse model of the ATR-X syndrome.
- reference: PMID:26773061
  title: "New players in heterochromatin silencing: histone variant H3.3 and the ATRX/DAXX chaperone."
- reference: PMID:28293299
  title: Identification of epigenetic signature associated with alpha thalassemia/mental retardation X-linked syndrome.
- reference: PMID:36292677
  title: "Phenotypic Spectrum and Molecular Findings in 17 ATR-X Syndrome Italian Patients: Some New Insights."
- reference: PMID:37925436
  title: Systemic and intrinsic functions of ATRX in glial cell fate and CNS myelination in male mice.
- reference: PMID:39363269
  title: "Identification of a Novel Frameshift variant of the ATRX gene: a Case Report and Review of the genotype-phenotype relationship."
- reference: PMID:39741769
  title: Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in ATR-X syndrome. Case report and literature review.
- reference: CGGV:assertion_5296ecdf-b709-47bd-9032-daec8b91e300-2021-09-28T220000.000Z
  title: ATRX / ATR-X-related syndrome (Definitive)

external_assertions:
- name: ClinGen ATRX gene-disease validity assertion
  source: ClinGen
  assertion_type: gene_disease_validity
  external_id: CGGV:assertion_5296ecdf-b709-47bd-9032-daec8b91e300-2021-09-28T220000.000Z
  url: https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_5296ecdf-b709-47bd-9032-daec8b91e300-2021-09-28T220000.000Z
  description: >-
    ClinGen classifies the X-linked ATRX–ATR-X-related syndrome relationship at
    the MONDO:0016980 umbrella as Definitive.
  evidence:
  - reference: CGGV:assertion_5296ecdf-b709-47bd-9032-daec8b91e300-2021-09-28T220000.000Z
    reference_title: ATRX / ATR-X-related syndrome (Definitive)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ATRX | HGNC:886 | ATR-X-related syndrome | MONDO:0016980 | XL | Definitive"
    explanation: >-
      The generated ClinGen record anchors the gene, umbrella disease identity,
      X-linked inheritance, and definitive classification.
has_subtypes:
- name: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome
  display_name: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome
  description: >-
    Curation interpretation: this is the conventional ATR-X label associated
    with alpha-thalassemia or HbH inclusions. Alpha-thalassemia is variable
    rather than required, so this child is represented as a historical clinical
    label within the shared ATRX spectrum, not as a separate molecular
    mechanism.
  subtype_term:
    preferred_term: alpha thalassemia-X-linked intellectual disability syndrome
    term:
      id: MONDO:0010519
      label: alpha thalassemia-X-linked intellectual disability syndrome
  evidence:
  - reference: PMID:20301622
    reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Alpha-thalassemia X-linked intellectual disability (ATR-X) syndrome is characterized by distinctive craniofacial features, genital anomalies, hypotonia, and mild-to-profound developmental delay / intellectual disability (DD/ID)."
    explanation: >-
      GeneReviews provides the established clinical identity for the
      alpha-thalassemia-associated label.
- name: Intellectual Disability-Hypotonic Facies Syndrome, X-Linked 1
  display_name: Intellectual Disability-Hypotonic Facies Syndrome, X-Linked 1
  description: >-
    Curation interpretation: because MRXHF1 and ATR-X share the causal gene and
    numerous reported manifestations, this record represents MRXHF1 as an
    overlapping historical or nosologic child within the ATR-X-related
    spectrum, not as a mutually exclusive HbH-negative biological subtype.
  subtype_term:
    preferred_term: intellectual disability-hypotonic facies syndrome, X-linked, 1
    term:
      id: MONDO:0010663
      label: intellectual disability-hypotonic facies syndrome, X-linked, 1
  evidence:
  - reference: PMID:39363269
    reference_title: "Identification of a Novel Frameshift variant of the ATRX gene: a Case Report and Review of the genotype-phenotype relationship."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "X-linked intellectual disability-hypotonic facies syndrome-1 (MRXHF1) and Alpha-thalassemia X-linked intellectual disability (ATR-X) syndrome are caused by pathogenic variant in the ATRX gene"
    explanation: >-
      The report explicitly identifies both labels as ATRX-associated and
      describes a shared broad clinical spectrum.
  - reference: PMID:39363269
    reference_title: "Identification of a Novel Frameshift variant of the ATRX gene: a Case Report and Review of the genotype-phenotype relationship."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Syndromes caused by ATRX germline mutation share"
    explanation: >-
      The review documents substantial phenotypic overlap across syndromes
      caused by germline ATRX variants.

prevalence:
- population: Male newborns
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_low: 2.5
  rate_high: 3.333333
  notes: >-
    The literature review reports an estimated birth prevalence of one in
    30,000 to one in 40,000 male newborns.
  evidence:
  - reference: PMID:39363269
    reference_title: "Identification of a Novel Frameshift variant of the ATRX gene: a Case Report and Review of the genotype-phenotype relationship."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "estimated prevalence of 1/30,000–1/40,000 in male newborns"
    explanation: >-
      The source explicitly reports the sex-specific newborn prevalence range;
      its reciprocal corresponds to 2.5–3.33 cases per 100,000 male births.

inheritance:
- name: X-linked inheritance
  inheritance_term:
    preferred_term: X-linked inheritance
    term:
      id: HP:0001417
      label: X-linked inheritance
  description: >-
    ATR-X-related syndrome is inherited in an X-linked manner. A pathogenic
    variant may be inherited from a heterozygous mother or arise de novo.
  evidence:
  - reference: PMID:20301622
    reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ATR-X syndrome is inherited in an X-linked manner."
    explanation: GeneReviews supports the broad X-linked mode used at the umbrella level.
  - reference: PMID:20301622
    reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mother of a proband may be heterozygous (i.e., a carrier) or the affected"
    explanation: >-
      GeneReviews supports maternal heterozygosity and transmission.
  - reference: PMID:20301622
    reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "individual may have a de novo pathogenic variant."
    explanation: GeneReviews also documents de novo occurrence.

mechanistic_hypotheses:
- hypothesis_group_id: atrx_chromatin_dysregulation
  hypothesis_label: ATRX Chromatin and Transcriptional Dysregulation
  status: CANONICAL
  description: >-
    Impaired ATRX chromatin-remodeling activity disrupts ATRX-DAXX-dependent
    heterochromatin regulation and tandem-repeat-associated gene expression,
    producing a multisystem developmental disorder.
  evidence:
  - reference: PMID:7697714
    reference_title: Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The complex ATR-X phenotype suggests that XH2, when mutated, down-regulates expression of several genes, including the alpha-globin genes, indicating that it could be a global transcriptional regulator."
    explanation: >-
      The foundational report supports broad transcriptional dysregulation as
      the canonical disease model.
  - reference: PMID:12953102
    reference_title: The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "ATRX and Daxx are components of an ATP-dependent chromatin-remodeling"
    explanation: >-
      Biochemical evidence supports the ATRX-DAXX chromatin-remodeling arm of
      the canonical model.
  - reference: PMID:21029860
    reference_title: ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Genes associated with these TRs can be dysregulated when ATRX is"
    explanation: >-
      The study supports tandem-repeat-associated transcriptional
      dysregulation in the canonical model.
- hypothesis_group_id: atrx_sertoli_androgen_model
  hypothesis_label: Sertoli Cell and Androgen-Signaling Model
  status: EMERGING
  description: >-
    Mouse Sertoli-cell loss of Atrx causes proliferative arrest and apoptosis
    and perturbs androgen-receptor-dependent transcription. This is a candidate
    explanation for human genital anomalies, not an established direct human
    causal chain.
  evidence:
  - reference: PMID:21427128
    reference_title: Defective survival of proliferating Sertoli cells and androgen receptor function in a mouse model of the ATR-X syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "ScAtrxKO mice developed small testes and discontinuous tubules, due to prolonged G2/M phase and apoptosis of proliferating Sertoli cells during fetal life."
    explanation: The conditional mouse model supports this emerging hypothesis.
- hypothesis_group_id: atrx_glial_myelination_model
  hypothesis_label: Oligodendrocyte and Myelination Model
  status: EMERGING
  description: >-
    Mouse ATRX loss impairs oligodendrocyte-progenitor differentiation and
    myelination. The extent to which this model explains human white-matter
    abnormalities remains unresolved.
  evidence:
  - reference: PMID:37925436
    reference_title: Systemic and intrinsic functions of ATRX in glial cell fate and CNS myelination in male mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These functions of ATRX identified in mice could explain white matter pathogenesis observed in ATR-X syndrome patients."
    explanation: The authors explicitly frame the mouse-to-human link as provisional.

pathophysiology:
- name: ATRX Chromatin-Remodeling Dysfunction
  conforms_to: "epigenetic_machinery_neurodevelopmental_dysregulation#Epigenetic Machinery Component Haploinsufficiency"
  description: >-
    Pathogenic constitutional ATRX variants impair an ATP-dependent chromatin
    remodeler of the SWI/SNF family. Clinically observed alleles are often
    described as hypomorphic; this node therefore models impaired ATRX function
    without asserting that every patient allele is a complete null. The defect
    alters chromatin targeting or remodeling and dysregulates transcription
    across multiple genomic contexts.
  role: trigger
  gene:
    preferred_term: ATRX
    term:
      id: hgnc:886
      label: ATRX
  biological_processes:
  - preferred_term: chromatin remodeling
    term:
      id: GO:0006338
      label: chromatin remodeling
    modifier: DECREASED
  - preferred_term: regulation of DNA-templated transcription
    term:
      id: GO:0006355
      label: regulation of DNA-templated transcription
    modifier: ABNORMAL
  evidence:
  - reference: PMID:36292677
    reference_title: "Phenotypic Spectrum and Molecular Findings in 17 ATR-X Syndrome Italian Patients: Some New Insights."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ATR-X syndrome is a rare X-linked congenital disorder caused by hypomorphic mutations in the ATRX gene."
    explanation: >-
      The clinical cohort supports pathogenic hypomorphic ATRX impairment as
      the initiating lesion.
  - reference: PMID:7697714
    reference_title: Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The complex ATR-X phenotype suggests that XH2, when mutated, down-regulates expression of several genes, including the alpha-globin genes, indicating that it could be a global transcriptional regulator."
    explanation: >-
      The foundational report links ATRX mutation to broad transcriptional
      dysregulation, including alpha-globin downregulation.
  - reference: PMID:12953102
    reference_title: The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "ATRX and Daxx are components of an ATP-dependent chromatin-remodeling"
    explanation: >-
      The biochemical study directly supports the ATP-dependent
      chromatin-remodeling description.
  - reference: PMID:21029860
    reference_title: ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "ATRX is an X-linked gene of the SWI/SNF family"
    explanation: The study supports classification of ATRX in the SWI/SNF family.
  downstream:
  - target: ATRX-DAXX Heterochromatin Remodeling Impairment
    causal_link_type: DIRECT
    description: >-
      Impaired ATRX function disrupts its DAXX-associated chromatin-remodeling
      activity at heterochromatin.
    hypothesis_groups:
    - atrx_chromatin_dysregulation
    evidence:
    - reference: PMID:12953102
      reference_title: The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Taken together, the results suggest that ATRX functions in conjunction with Daxx in a novel chromatin-remodeling complex. The defects in ATRX syndrome may result from inappropriate expression of genes controlled by this complex."
      explanation: >-
        Cell-based studies establish the ATRX-DAXX chromatin-remodeling
        complex and connect its disruption to abnormal gene expression.
  - target: Tandem-Repeat-Associated Gene Dysregulation
    causal_link_type: DIRECT
    description: >-
      ATRX impairment disrupts binding and transcriptional regulation at
      tandem-repeat-associated loci.
    hypothesis_groups:
    - atrx_chromatin_dysregulation
    evidence:
    - reference: PMID:21029860
      reference_title: ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Here we show that ATRX binds to tandem repeat (TR) sequences in both telomeres and euchromatin. Genes associated with these TRs can be dysregulated when ATRX is mutated, and the change in expression is determined by the size of the TR, producing skewed allelic expression."
      explanation: >-
        The study directly demonstrates ATRX binding at tandem repeats and
        dysregulation after ATRX mutation.
  - target: Sertoli Cell Survival and Androgen-Signaling Impairment
    causal_link_type: DIRECT
    description: >-
      This emerging branch captures the tissue-specific consequence observed
      after Atrx loss in mouse Sertoli cells.
    hypothesis_groups:
    - atrx_sertoli_androgen_model
    evidence:
    - reference: PMID:21427128
      reference_title: Defective survival of proliferating Sertoli cells and androgen receptor function in a mouse model of the ATR-X syndrome.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "ScAtrxKO mice developed small testes and discontinuous tubules, due to prolonged G2/M phase and apoptosis of proliferating Sertoli cells during fetal life."
      explanation: >-
        A conditional mouse model supports this tissue-specific branch but
        does not establish the complete human causal pathway.
  - target: Oligodendrocyte Differentiation and Myelination Impairment
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      In mice, ATRX loss affects myelination through systemic thyroid-hormone
      effects and OPC-intrinsic differentiation, so this emerging branch has
      known intervening routes rather than a single direct link.
    hypothesis_groups:
    - atrx_glial_myelination_model
    evidence:
    - reference: PMID:37925436
      reference_title: Systemic and intrinsic functions of ATRX in glial cell fate and CNS myelination in male mice.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "We show that loss of ATRX leads to myelination deficits in male mice that are partially rectified upon systemic thyroxine administration."
      explanation: >-
        The mouse result supports an ATRX-dependent myelination branch while
        leaving its human contribution uncertain.
  - target: Multisystem Developmental and Clinical Consequences
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The broad human phenotype follows ATRX dysfunction through incompletely
      resolved tissue- and locus-specific intermediates.
    hypothesis_groups:
    - atrx_chromatin_dysregulation
    evidence:
    - reference: PMID:7697714
      reference_title: Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome).
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The complex ATR-X phenotype suggests that XH2, when mutated, down-regulates expression of several genes, including the alpha-globin genes, indicating that it could be a global transcriptional regulator."
      explanation: >-
        The foundational report supports a multisystem consequence of broad
        gene dysregulation while not resolving each downstream intermediate.

- name: ATRX-DAXX Heterochromatin Remodeling Impairment
  conforms_to: "epigenetic_machinery_neurodevelopmental_dysregulation#Permissive-Repressive Chromatin State Imbalance"
  description: >-
    ATRX cooperates with DAXX in a chromatin-remodeling and histone-chaperone
    complex. The prevailing model places H3.3 at heterochromatin to help
    maintain H3K9me3-associated silencing. ATR-X blood samples also show a
    specific methylation signature enriched near pericentromeric and telomeric
    regions, consistent with disturbed heterochromatin regulation.
  biological_processes:
  - preferred_term: heterochromatin organization
    term:
      id: GO:0070828
      label: heterochromatin organization
    modifier: ABNORMAL
  - preferred_term: nucleosome assembly
    term:
      id: GO:0006334
      label: nucleosome assembly
    modifier: ABNORMAL
  evidence:
  - reference: PMID:12953102
    reference_title: The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Taken together, the results suggest that ATRX functions in conjunction with Daxx in a novel chromatin-remodeling complex. The defects in ATRX syndrome may result from inappropriate expression of genes controlled by this complex."
    explanation: >-
      The study establishes the ATRX-DAXX complex and its proposed disease
      relevance.
  - reference: PMID:26773061
    reference_title: "New players in heterochromatin silencing: histone variant H3.3 and the ATRX/DAXX chaperone."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "We provide an overview of the individual components (ATRX, DAXX and/or H3.3) tested in each study and propose a model where the ATRX/DAXX chaperone complex deposits H3.3 to maintain the H3K9me3 modification at heterochromatin throughout the genome."
    explanation: >-
      This mechanistic review supports the H3.3-deposition and H3K9me3
      maintenance model.
  - reference: PMID:28293299
    reference_title: Identification of epigenetic signature associated with alpha thalassemia/mental retardation X-linked syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "differentially methylated regions showed evidence of preferential clustering in pericentromeric and telometric chromosomal regions, areas where ATRX has multiple functions related to maintenance of heterochromatin and genomic integrity"
    explanation: >-
      The human blood methylation signature is consistent with disturbance at
      ATRX-associated heterochromatic regions.

- name: Tandem-Repeat-Associated Gene Dysregulation
  description: >-
    ATRX binds G-rich tandem-repeat sequences in telomeres and euchromatin,
    including sequences capable of forming non-B DNA structures. ATRX mutation
    can produce repeat-size-dependent dysregulation and skewed allelic
    expression at associated genes, including downregulation of alpha-globin.
  biological_processes:
  - preferred_term: regulation of DNA-templated transcription
    term:
      id: GO:0006355
      label: regulation of DNA-templated transcription
    modifier: ABNORMAL
  evidence:
  - reference: PMID:21029860
    reference_title: ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Here we show that ATRX binds to tandem repeat (TR) sequences in both telomeres and euchromatin. Genes associated with these TRs can be dysregulated when ATRX is mutated, and the change in expression is determined by the size of the TR, producing skewed allelic expression."
    explanation: >-
      The study demonstrates the repeat-binding and allele-specific expression
      mechanism.
  - reference: PMID:21029860
    reference_title: ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Many of the TRs are G rich and predicted to form non-B DNA structures (including G-quadruplex) in vivo. We show that ATRX binds G-quadruplex structures in vitro"
    explanation: >-
      The experiments support binding to G-rich repeat structures as a
      molecular basis for the repeat-associated effect.
  downstream:
  - target: Alpha-Thalassemia with HbH Hemoglobin
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Repeat-associated transcriptional dysregulation includes reduced
      alpha-globin expression and provides a mechanistic link to HbH.
    hypothesis_groups:
    - atrx_chromatin_dysregulation
    evidence:
    - reference: PMID:21029860
      reference_title: ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "ATRX is an X-linked gene of the SWI/SNF family, mutations in which cause syndromal mental retardation and downregulation of α-globin expression."
      explanation: >-
        The paper connects ATRX mutation to alpha-globin downregulation; the
        intervening steps to the clinical HbH phenotype remain incomplete.

- name: Sertoli Cell Survival and Androgen-Signaling Impairment
  description: >-
    In a Sertoli-cell-specific Atrx knockout mouse, proliferating Sertoli cells
    show prolonged G2/M and apoptosis. ATRX also physically interacts with the
    androgen receptor and promotes expression of androgen-dependent genes.
    These observations form an emerging model for human genital anomalies.
  cell_types:
  - preferred_term: Sertoli cell
    term:
      id: CL:0000216
      label: Sertoli cell
  biological_processes:
  - preferred_term: regulation of DNA-templated transcription
    term:
      id: GO:0006355
      label: regulation of DNA-templated transcription
    modifier: ABNORMAL
  evidence:
  - reference: PMID:21427128
    reference_title: Defective survival of proliferating Sertoli cells and androgen receptor function in a mouse model of the ATR-X syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "ScAtrxKO mice developed small testes and discontinuous tubules, due to prolonged G2/M phase and apoptosis of proliferating Sertoli cells during fetal life."
    explanation: >-
      Conditional mouse deletion demonstrates defective fetal Sertoli-cell
      survival.
  - reference: PMID:21427128
    reference_title: Defective survival of proliferating Sertoli cells and androgen receptor function in a mouse model of the ATR-X syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These data suggest that ATRX can directly enhance the expression of androgen-dependent genes through physical interaction with AR."
    explanation: >-
      Mouse and Sertoli-cell experiments support an ATRX-androgen-receptor
      transcriptional interaction.
  downstream:
  - target: Genital Anomalies
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The mouse Sertoli/androgen findings are a candidate, not proven, route to
      the broad human genital-anomaly spectrum.
    hypothesis_groups:
    - atrx_sertoli_androgen_model
    evidence:
    - reference: PMID:21427128
      reference_title: Defective survival of proliferating Sertoli cells and androgen receptor function in a mouse model of the ATR-X syndrome.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "ScAtrxKO mice developed small testes and discontinuous tubules, due to prolonged G2/M phase and apoptosis of proliferating Sertoli cells during fetal life."
      explanation: >-
        The animal model provides partial mechanistic support but does not
        establish direct causation of the human phenotype.
  - target: Hypospadias
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Altered Sertoli-cell survival and androgen-dependent transcription are an
      emerging candidate pathway to hypospadias.
    hypothesis_groups:
    - atrx_sertoli_androgen_model
    evidence:
    - reference: PMID:21427128
      reference_title: Defective survival of proliferating Sertoli cells and androgen receptor function in a mouse model of the ATR-X syndrome.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "These data suggest that ATRX can directly enhance the expression of androgen-dependent genes through physical interaction with AR."
      explanation: >-
        The model supports androgen-signaling impairment, but the human
        hypospadias link remains indirect.
  - target: Cryptorchidism
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Altered Sertoli-cell survival and androgen-dependent transcription are an
      emerging candidate pathway to cryptorchidism.
    hypothesis_groups:
    - atrx_sertoli_androgen_model
    evidence:
    - reference: PMID:21427128
      reference_title: Defective survival of proliferating Sertoli cells and androgen receptor function in a mouse model of the ATR-X syndrome.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "ScAtrxKO mice developed small testes and discontinuous tubules, due to prolonged G2/M phase and apoptosis of proliferating Sertoli cells during fetal life."
      explanation: >-
        The mouse testis phenotype provides partial support for this
        tissue-specific hypothesis, not a direct human causal demonstration.

- name: Oligodendrocyte Differentiation and Myelination Impairment
  description: >-
    Mouse ATRX loss causes myelination deficits and impairs oligodendrocyte
    progenitor differentiation, favoring astrocytic differentiation. The study
    proposes that these functions could explain white-matter pathology in
    people with ATR-X syndrome; human causal validation remains needed.
  cell_types:
  - preferred_term: oligodendrocyte precursor cell
    term:
      id: CL:0002453
      label: oligodendrocyte precursor cell
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: oligodendrocyte differentiation
    term:
      id: GO:0048709
      label: oligodendrocyte differentiation
    modifier: DECREASED
  - preferred_term: myelination
    term:
      id: GO:0042552
      label: myelination
    modifier: DECREASED
  evidence:
  - reference: PMID:37925436
    reference_title: Systemic and intrinsic functions of ATRX in glial cell fate and CNS myelination in male mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We show that loss of ATRX leads to myelination deficits in male mice that are partially rectified upon systemic thyroxine administration."
    explanation: >-
      The mouse experiment establishes an ATRX-dependent myelination deficit;
      it does not justify thyroxine as a human treatment.
  - reference: PMID:37925436
    reference_title: Systemic and intrinsic functions of ATRX in glial cell fate and CNS myelination in male mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Targeted ATRX inactivation in either neurons or oligodendrocyte progenitor cells (OPCs) reveals OPC-intrinsic effects on myelination."
    explanation: >-
      Targeted mouse experiments support an OPC-intrinsic contribution to the
      myelination phenotype.

- name: Multisystem Developmental and Clinical Consequences
  conforms_to: "epigenetic_machinery_neurodevelopmental_dysregulation#Intellectual Disability with Growth and Craniofacial Dysmorphism"
  description: >-
    Human ATR-X-related syndrome has a recognizable multisystem phenotype.
    This consequence node connects the clinically observed manifestations while
    explicitly leaving the molecular and tissue-specific intermediates
    unresolved; it does not imply that the upstream chromatin defect directly
    causes each feature in one step.
  evidence:
  - reference: PMID:20301622
    reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Alpha-thalassemia X-linked intellectual disability (ATR-X) syndrome is characterized by distinctive craniofacial features, genital anomalies, hypotonia, and mild-to-profound developmental delay / intellectual disability (DD/ID)."
    explanation: >-
      GeneReviews establishes the core multisystem clinical presentation.
  - reference: PMID:36292677
    reference_title: "Phenotypic Spectrum and Molecular Findings in 17 ATR-X Syndrome Italian Patients: Some New Insights."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A typical phenotype is well defined, with cognitive impairment, characteristic facial dysmorphism, hypotonia, gastrointestinal, skeletal, urogenital, and hematological anomalies as characteristic features."
    explanation: >-
      The cohort supports the broader gastrointestinal, skeletal, urogenital,
      and hematologic spectrum.
  downstream:
  - target: Intellectual Disability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301622
      reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "mild-to-profound developmental delay / intellectual disability (DD/ID)"
      explanation: >-
        GeneReviews supports the association; intervening causal steps are not
        specified.
  - target: Global Developmental Delay
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301622
      reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "mild-to-profound developmental delay / intellectual disability (DD/ID)"
      explanation: >-
        GeneReviews supports the association; intervening causal steps are not
        specified.
  - target: Hypotonia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301622
      reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "is characterized by distinctive craniofacial features, genital anomalies, hypotonia, and mild-to-profound developmental delay"
      explanation: >-
        GeneReviews supports the association; intervening causal steps are not
        specified.
  - target: Distinctive Craniofacial Features
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301622
      reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Craniofacial abnormalities include small head circumference, telecanthus or widely spaced eyes, short triangular nose, tented upper lip, and thick or everted lower lip with coarsening of the facial features over time."
      explanation: >-
        GeneReviews supports the facial phenotype while the causal
        intermediates remain unresolved.
  - target: Microcephaly
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301622
      reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Craniofacial abnormalities include small head circumference"
      explanation: >-
        GeneReviews supports small head circumference as part of the
        presentation.
  - target: Telecanthus
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301622
      reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "telecanthus or widely spaced eyes, short triangular nose, tented upper lip"
      explanation: GeneReviews supports telecanthus as part of the facial phenotype.
  - target: Everted Lower Lip
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301622
      reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "tented upper lip, and thick or everted lower lip with coarsening of the facial features over time"
      explanation: GeneReviews supports the thick or everted lower lip feature.
  - target: Genital Anomalies
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301622
      reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "genital anomalies comprise a range from hypospadias and undescended testicles, to severe hypospadias and ambiguous genitalia, to normal-appearing female external genitalia"
      explanation: GeneReviews supports the broad genital-anomaly spectrum.
  - target: Hypospadias
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301622
      reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "a range from hypospadias and undescended testicles, to severe hypospadias and ambiguous genitalia"
      explanation: GeneReviews supports hypospadias as part of the spectrum.
  - target: Cryptorchidism
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301622
      reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "a range from hypospadias and undescended testicles"
      explanation: GeneReviews supports undescended testicles in the spectrum.
  - target: Alpha-Thalassemia with HbH Hemoglobin
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301622
      reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Alpha-thalassemia, observed in about 75% of affected individuals, is mild and typically does not require treatment."
      explanation: GeneReviews supports alpha-thalassemia as a variable feature.
  - target: Seizures
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301622
      reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Treatment of manifestations: DD/ID, seizures, gastrointestinal manifestations and feeding difficulties, excessive drooling, and genital anomalies are managed per standard of care."
      explanation: GeneReviews identifies seizures among managed manifestations.
  - target: Feeding Difficulties
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301622
      reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "gastrointestinal manifestations and feeding difficulties, excessive drooling"
      explanation: GeneReviews identifies feeding difficulties as a manifestation.
  - target: Drooling
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301622
      reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "feeding difficulties, excessive drooling, and genital anomalies are managed per standard of care"
      explanation: GeneReviews identifies excessive drooling as a manifestation.
  - target: Constipation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:39741769
      reference_title: Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in ATR-X syndrome. Case report and literature review.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "significant gastrointestinal (GI) complications, such as abdominal distension, chronic constipation, feeding difficulties, gastroesophageal reflux"
      explanation: The clinical report identifies chronic constipation as a gastrointestinal manifestation.
  - target: Gastroesophageal Reflux
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:39741769
      reference_title: Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in ATR-X syndrome. Case report and literature review.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "significant gastrointestinal (GI) complications, such as abdominal distension, chronic constipation, feeding difficulties, gastroesophageal reflux"
      explanation: The clinical report identifies gastroesophageal reflux as a gastrointestinal manifestation.
  - target: Skeletal Anomalies
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:36292677
      reference_title: "Phenotypic Spectrum and Molecular Findings in 17 ATR-X Syndrome Italian Patients: Some New Insights."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "with cognitive impairment, characteristic facial dysmorphism, hypotonia, gastrointestinal, skeletal, urogenital, and hematological anomalies as characteristic features"
      explanation: The clinical cohort supports skeletal manifestations.
phenotypes:
- category: Phenotypic
  name: Intellectual Disability
  description: >-
    Mild-to-profound intellectual disability is a defining feature of the
    ATR-X-related clinical spectrum.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:20301622
    reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Alpha-thalassemia X-linked intellectual disability (ATR-X) syndrome is characterized by distinctive craniofacial features, genital anomalies, hypotonia, and mild-to-profound developmental delay / intellectual disability (DD/ID)."
    explanation: GeneReviews lists intellectual disability as a core feature.
- category: Phenotypic
  name: Global Developmental Delay
  description: >-
    Affected individuals can have mild-to-profound developmental delay.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:20301622
    reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mild-to-profound developmental delay / intellectual disability (DD/ID)"
    explanation: GeneReviews documents developmental delay in the syndrome.
- category: Phenotypic
  name: Hypotonia
  description: Hypotonia is a characteristic manifestation.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:20301622
    reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "is characterized by distinctive craniofacial features, genital anomalies, hypotonia, and mild-to-profound developmental delay"
    explanation: GeneReviews lists hypotonia among the characterizing features.
- category: Phenotypic
  name: Distinctive Craniofacial Features
  description: >-
    The facial gestalt includes telecanthus or widely spaced eyes, a short
    triangular nose, a tented upper lip, and a thick or everted lower lip, with
    coarsening over time.
  phenotype_term:
    preferred_term: Abnormal facial shape
    term:
      id: HP:0001999
      label: Abnormal facial shape
  evidence:
  - reference: PMID:20301622
    reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Craniofacial abnormalities include small head circumference, telecanthus or widely spaced eyes, short triangular nose, tented upper lip, and thick or everted lower lip with coarsening of the facial features over time."
    explanation: GeneReviews describes the characteristic craniofacial pattern.
- category: Phenotypic
  name: Microcephaly
  description: Small head circumference is part of the craniofacial presentation.
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  evidence:
  - reference: PMID:20301622
    reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Craniofacial abnormalities include small head circumference"
    explanation: GeneReviews documents small head circumference.
- category: Phenotypic
  name: Telecanthus
  description: Telecanthus or widely spaced eyes contributes to the facial gestalt.
  phenotype_term:
    preferred_term: Telecanthus
    term:
      id: HP:0000506
      label: Telecanthus
  evidence:
  - reference: PMID:20301622
    reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "telecanthus or widely spaced eyes, short triangular nose, tented upper lip"
    explanation: GeneReviews lists telecanthus among the facial features.
- category: Phenotypic
  name: Everted Lower Lip
  description: A thick or everted lower lip is part of the recognizable facial pattern.
  phenotype_term:
    preferred_term: Everted lower lip vermilion
    term:
      id: HP:0000232
      label: Everted lower lip vermilion
  evidence:
  - reference: PMID:20301622
    reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "tented upper lip, and thick or everted lower lip with coarsening of the facial features over time"
    explanation: GeneReviews describes the thick or everted lower lip.
- category: Phenotypic
  name: Genital Anomalies
  description: >-
    Genital anomalies in affected 46,XY individuals range from hypospadias and
    undescended testes to ambiguous or female-appearing external genitalia.
  phenotype_term:
    preferred_term: Abnormal male external genitalia morphology
    term:
      id: HP:0000032
      label: Abnormal male external genitalia morphology
  evidence:
  - reference: PMID:20301622
    reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "genital anomalies comprise a range from hypospadias and undescended testicles, to severe hypospadias and ambiguous genitalia, to normal-appearing female external genitalia"
    explanation: GeneReviews describes the full genital-anomaly spectrum.
- category: Phenotypic
  name: Hypospadias
  description: Hypospadias occurs within the genital-anomaly spectrum.
  phenotype_term:
    preferred_term: Hypospadias
    term:
      id: HP:0000047
      label: Hypospadias
  evidence:
  - reference: PMID:20301622
    reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a range from hypospadias and undescended testicles, to severe hypospadias and ambiguous genitalia"
    explanation: GeneReviews explicitly lists hypospadias.
- category: Phenotypic
  name: Cryptorchidism
  description: Undescended testes occur within the genital-anomaly spectrum.
  phenotype_term:
    preferred_term: Cryptorchidism
    term:
      id: HP:0000028
      label: Cryptorchidism
  evidence:
  - reference: PMID:20301622
    reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a range from hypospadias and undescended testicles"
    explanation: GeneReviews explicitly lists undescended testicles.
- category: Phenotypic
  name: Alpha-Thalassemia with HbH Hemoglobin
  description: >-
    Mild alpha-thalassemia with HbH inclusions is present in about 75% of
    affected individuals and usually does not require treatment. Its absence
    does not exclude ATR-X-related syndrome.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: HbH hemoglobin
    term:
      id: HP:0011903
      label: HbH hemoglobin
  evidence:
  - reference: PMID:20301622
    reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Alpha-thalassemia, observed in about 75% of affected individuals, is mild and typically does not require treatment."
    explanation: >-
      The approximately 75% estimate supports both the association and the
      FREQUENT band.
  - reference: PMID:7697714
    reference_title: Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The ATR-X syndrome is an X-linked disorder comprising severe psychomotor retardation, characteristic facial features, genital abnormalities, and alpha-thalassemia."
    explanation: The foundational clinical description includes alpha-thalassemia.
  - reference: PMID:39363269
    reference_title: "Identification of a Novel Frameshift variant of the ATRX gene: a Case Report and Review of the genotype-phenotype relationship."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "form beta tetramers (HbH)"
    explanation: >-
      The review explicitly connects reduced alpha-globin expression to HbH
      tetramer formation.
- category: Phenotypic
  name: Seizures
  description: Seizures occur in part of the clinical spectrum.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:20301622
    reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment of manifestations: DD/ID, seizures, gastrointestinal manifestations and feeding difficulties, excessive drooling, and genital anomalies are managed per standard of care."
    explanation: GeneReviews includes seizures among managed manifestations.
- category: Phenotypic
  name: Feeding Difficulties
  description: Feeding difficulties are a recognized source of morbidity.
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  evidence:
  - reference: PMID:20301622
    reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "gastrointestinal manifestations and feeding difficulties, excessive drooling"
    explanation: GeneReviews documents feeding difficulties.
- category: Phenotypic
  name: Drooling
  description: Excessive drooling is a recognized manifestation.
  phenotype_term:
    preferred_term: Drooling
    term:
      id: HP:0002307
      label: Drooling
  evidence:
  - reference: PMID:20301622
    reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "feeding difficulties, excessive drooling, and genital anomalies are managed per standard of care"
    explanation: GeneReviews documents excessive drooling.
- category: Phenotypic
  name: Constipation
  description: Chronic constipation is a reported gastrointestinal manifestation.
  phenotype_term:
    preferred_term: Constipation
    term:
      id: HP:0002019
      label: Constipation
  evidence:
  - reference: PMID:39741769
    reference_title: Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in ATR-X syndrome. Case report and literature review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "significant gastrointestinal (GI) complications, such as abdominal distension, chronic constipation, feeding difficulties, gastroesophageal reflux"
    explanation: The clinical report explicitly documents chronic constipation.
- category: Phenotypic
  name: Gastroesophageal Reflux
  description: Gastroesophageal reflux is a reported gastrointestinal manifestation.
  phenotype_term:
    preferred_term: Gastroesophageal reflux
    term:
      id: HP:0002020
      label: Gastroesophageal reflux
  evidence:
  - reference: PMID:39741769
    reference_title: Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in ATR-X syndrome. Case report and literature review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "significant gastrointestinal (GI) complications, such as abdominal distension, chronic constipation, feeding difficulties, gastroesophageal reflux"
    explanation: The clinical report explicitly documents gastroesophageal reflux.
- category: Phenotypic
  name: Skeletal Anomalies
  description: Skeletal abnormalities are part of the broader clinical spectrum.
  phenotype_term:
    preferred_term: Abnormality of the skeletal system
    term:
      id: HP:0000924
      label: Abnormality of the skeletal system
  evidence:
  - reference: PMID:36292677
    reference_title: "Phenotypic Spectrum and Molecular Findings in 17 ATR-X Syndrome Italian Patients: Some New Insights."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A typical phenotype is well defined, with cognitive impairment, characteristic facial dysmorphism, hypotonia, gastrointestinal, skeletal, urogenital, and hematological anomalies as characteristic features."
    explanation: The cohort identifies skeletal anomalies as characteristic.
diagnosis:
- name: Molecular Confirmation of ATRX-Related Disease
  description: >-
    In a patient with suggestive findings and a 46,XY karyotype, identification
    of a hemizygous pathogenic ATRX variant establishes the molecular diagnosis.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: NCIT:C19770
      label: Molecular Analysis
  results: A hemizygous pathogenic ATRX variant confirms ATR-X-related syndrome in the appropriate clinical context.
  evidence:
  - reference: PMID:20301622
    reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of ATR-X syndrome is established in a proband with suggestive findings, a 46,XY karyotype, and a hemizygous pathogenic variant in ATRX identified by molecular genetic testing."
    explanation: GeneReviews states the molecular diagnostic criterion.
- name: Peripheral-Blood DNA Methylation Episignature
  description: >-
    A highly specific blood DNA methylation episignature can support diagnosis
    in phenotypically complex cases or help interpret an ATRX variant of
    uncertain significance. It is supportive rather than a standalone
    replacement for clinical and sequence interpretation.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: NCIT:C18020
      label: Diagnostic Procedure
  results: A matching ATR-X methylation episignature provides supportive molecular evidence.
  evidence:
  - reference: PMID:28293299
    reference_title: Identification of epigenetic signature associated with alpha thalassemia/mental retardation X-linked syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most significant methylation changes in the 14 genomic loci provide a unique epigenetic signature for this syndrome that may be used as a highly sensitive and specific diagnostic biomarker to support the diagnosis of ATR-X, particularly in patients with phenotypic complexity and in patients with ATRX gene sequence variants of unknown significance."
    explanation: >-
      The study supports the episignature specifically as an adjunct in complex
      cases and for uncertain variants.

genetic:
- name: ATRX Pathogenic Germline Variants
  gene_term:
    preferred_term: ATRX
    term:
      id: hgnc:886
      label: ATRX
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >-
    Pathogenic hemizygous ATRX variants impair chromatin-remodeling function.
    Constitutional alleles are often described as hypomorphic. A literature
    review of 63 patients reported epilepsy and urogenital, acoustic, and
    optical defects more often with frameshift than missense variants, but the
    small, heterogeneous retrospective sample is descriptive and not suitable
    for individual prognosis. Broad domain-specific genotype-phenotype
    correlations remain insufficient for routine prognostic use.
  evidence:
  - reference: PMID:20301622
    reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of ATR-X syndrome is established in a proband with suggestive findings, a 46,XY karyotype, and a hemizygous pathogenic variant in ATRX identified by molecular genetic testing."
    explanation: GeneReviews establishes hemizygous ATRX variants as causative.
  - reference: PMID:36292677
    reference_title: "Phenotypic Spectrum and Molecular Findings in 17 ATR-X Syndrome Italian Patients: Some New Insights."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ATR-X syndrome is a rare X-linked congenital disorder caused by hypomorphic mutations in the ATRX gene."
    explanation: The cohort supports impaired or hypomorphic constitutional alleles.
  - reference: PMID:36292677
    reference_title: "Phenotypic Spectrum and Molecular Findings in 17 ATR-X Syndrome Italian Patients: Some New Insights."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "specific ATRX protein domains are not well established and should not be used"
    explanation: >-
      The cohort cautions against routine prognostic use of broad
      domain-specific genotype-phenotype correlations.
  - reference: PMID:39363269
    reference_title: "Identification of a Novel Frameshift variant of the ATRX gene: a Case Report and Review of the genotype-phenotype relationship."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Epilepsy, congenital heart disease, urogenital defect, acoustic defect, and optical defect are more prevalent in patients with frameshift mutations compared to those with missense mutations."
    explanation: >-
      The review reports a descriptive variant-class association in a small,
      heterogeneous literature-derived cohort; it does not establish an
      individual-level prognostic relationship.
  - reference: CGGV:assertion_5296ecdf-b709-47bd-9032-daec8b91e300-2021-09-28T220000.000Z
    reference_title: ATRX / ATR-X-related syndrome (Definitive)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ATRX | HGNC:886 | ATR-X-related syndrome | MONDO:0016980 | XL | Definitive"
    explanation: ClinGen classifies the umbrella ATRX gene-disease relationship as definitive.

treatments:
- name: Supportive and Phenotype-Directed Care
  description: >-
    Management is supportive and individualized, including developmental and
    educational support and standard care for seizures, gastrointestinal and
    feeding problems, drooling, and genital anomalies.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301622
    reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment of manifestations: DD/ID, seizures, gastrointestinal manifestations and feeding difficulties, excessive drooling, and genital anomalies are managed per standard of care."
    explanation: GeneReviews supports manifestation-directed standard care.
- name: Genetic Counseling and Family Testing
  description: >-
    Counseling should address X-linked recurrence, carrier testing for at-risk
    females, and reproductive testing options once the familial ATRX variant is
    known.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:20301622
    reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Once the ATRX pathogenic variant in the family has been identified, carrier testing for at-risk females, prenatal testing for pregnancies at increased risk, and preimplantation genetic testing are possible."
    explanation: GeneReviews supports counseling and family-based testing options.
- name: Pyridostigmine for Severe Gastrointestinal Dysmotility
  description: >-
    Pyridostigmine produced reported benefit in one child with ATR-X syndrome
    and gastrointestinal dysmotility. This is an off-label single-case
    observation with limited pediatric evidence, not established syndrome
    management.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: pyridostigmine
      term:
        id: CHEBI:8665
        label: Pyridostigmine
  evidence:
  - reference: PMID:39741769
    reference_title: Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in ATR-X syndrome. Case report and literature review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report a patient with ATR-X syndrome suffering from gastrointestinal dysmotility and highlight the beneficial effects of pyridostigmine."
    explanation: The publication reports benefit in a single ATR-X case.
  - reference: PMID:39741769
    reference_title: Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in ATR-X syndrome. Case report and literature review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Knowledge about the role and appropriate dosage of pyridostigmine in GI motility disorders is limited."
    explanation: The same report explicitly limits confidence and dosing knowledge.

discussions:
- discussion_id: gap_atrx_mouse_tissue_models_human_translation
  prompt: >-
    To what extent do Sertoli-cell and oligodendrocyte phenotypes in conditional
    Atrx mouse models explain genital and white-matter manifestations in human
    ATR-X-related syndrome?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Sertoli Cell Survival and Androgen-Signaling Impairment
  - pathophysiology#Oligodendrocyte Differentiation and Myelination Impairment
  rationale: >-
    Conditional mouse studies provide tissue-specific mechanisms, but neither
    branch has been established as the causal route in human tissue. The glial
    study explicitly says the mouse functions could explain human white-matter
    pathology, and the Sertoli model does not directly reproduce or prove each
    human genital phenotype. Human cellular models and patient-correlated
    molecular readouts are needed before these branches are considered
    canonical.
  evidence:
  - reference: PMID:37925436
    reference_title: Systemic and intrinsic functions of ATRX in glial cell fate and CNS myelination in male mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These functions of ATRX identified in mice could explain white matter pathogenesis observed in ATR-X syndrome patients."
    explanation: The authors explicitly qualify translation from mouse to human.
- discussion_id: gap_atrx_osteosarcoma_tumor_predisposition
  prompt: >-
    Does germline ATRX dysfunction confer a clinically meaningful
    osteosarcoma or broader tumor predisposition, and through which mechanism?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#ATRX-DAXX Heterochromatin Remodeling Impairment
  rationale: >-
    GeneReviews reports osteosarcoma in only a few males with germline ATRX
    variants. The evidence is insufficient to assert a tumor-predisposition
    phenotype or surveillance recommendation, and a mechanistic link to
    heterochromatin or telomere dysfunction remains unestablished.
  evidence:
  - reference: PMID:20301622
    reference_title: Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Osteosarcoma has been reported in a few males with germline pathogenic variants."
    explanation: The rare reports motivate the gap without establishing predisposition.

clinical_trials: []
datasets: []
📚

References & Deep Research

References

12
PMID:20301622
Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
No top-level findings curated for this source.
PMID:7697714
Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome).
No top-level findings curated for this source.
PMID:12953102
The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies.
No top-level findings curated for this source.
PMID:21029860
ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner.
No top-level findings curated for this source.
PMID:21427128
Defective survival of proliferating Sertoli cells and androgen receptor function in a mouse model of the ATR-X syndrome.
No top-level findings curated for this source.
PMID:26773061
New players in heterochromatin silencing: histone variant H3.3 and the ATRX/DAXX chaperone.
No top-level findings curated for this source.
PMID:28293299
Identification of epigenetic signature associated with alpha thalassemia/mental retardation X-linked syndrome.
No top-level findings curated for this source.
PMID:36292677
Phenotypic Spectrum and Molecular Findings in 17 ATR-X Syndrome Italian Patients: Some New Insights.
No top-level findings curated for this source.
PMID:37925436
Systemic and intrinsic functions of ATRX in glial cell fate and CNS myelination in male mice.
No top-level findings curated for this source.
PMID:39363269
Identification of a Novel Frameshift variant of the ATRX gene: a Case Report and Review of the genotype-phenotype relationship.
No top-level findings curated for this source.
PMID:39741769
Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in ATR-X syndrome. Case report and literature review.
No top-level findings curated for this source.
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
1. Disease Information
Edison Scientific Literature 39 citations 2026-06-04T00:02:30.672658

1. Disease Information

1.1 Concise overview (current understanding)

ATR-X syndrome is a rare, primarily male-affecting X-linked neurodevelopmental disorder caused by hypomorphic germline variants in ATRX, characterized by intellectual disability (ID) often accompanied by alpha-thalassemia and multi-system congenital anomalies (facial dysmorphism, hypotonia, skeletal and urogenital abnormalities, and hematologic findings). (tillotson2023anewmouse pages 1-4, yuan2024mutantatrxpathogenesis pages 1-2, pang2023thechromatinremodeler pages 1-2)

1.2 Key identifiers and nomenclature

A structured summary of the identifiers and naming used in the retrieved literature is provided below.

Disease name Major synonyms / alternative names OMIM number(s) Inheritance Estimated prevalence Orphanet / MONDO / MeSH / ICD status in retrieved full text Key references (year, URL)
ATR-X syndrome ATRX syndrome; alpha-thalassemia/intellectual disability, X-linked; alpha-thalassemia X-linked intellectual disability syndrome; alpha-thalassemia mental retardation syndrome, X-linked OMIM: 301040 X-linked; primarily affects hemizygous males, with female carriers often minimally affected due to skewed X-inactivation (tillotson2023anewmouse pages 1-4, yuan2024mutantatrxpathogenesis pages 1-2) Rare; estimated at ~1/30,000-1/40,000 male newborns in one 2024 review/case synthesis; worldwide prevalence otherwise described as unknown (wang2024identificationofa pages 1-2, maganaacosta2025atrxfrom pages 13-13) Orphanet: not found in retrieved full text for this disease entry; MONDO: Not found in retrieved full text; MeSH: Not found in retrieved full text; ICD: Not found in retrieved full text Wang et al. 2024, https://doi.org/10.1186/s12887-024-05088-0; Tillotson et al. 2023, https://doi.org/10.1101/2023.01.25.525394; Yuan et al. 2024, https://doi.org/10.3389/fmolb.2024.1434398 (wang2024identificationofa pages 1-2, tillotson2023anewmouse pages 1-4, yuan2024mutantatrxpathogenesis pages 1-2)
ATRX-related disorder label noted in literature X-linked intellectual disability-hypotonic facies syndrome-1 (MRXHF1); ATRX gene-related syndromes OMIM: 309580 (MRXHF1, related ATRX-associated disorder noted in 2024 review/case report) X-linked (wang2024identificationofa pages 1-2) Not separately estimated in retrieved full text Orphanet: Not found in retrieved full text; MONDO: Not found in retrieved full text; MeSH: Not found in retrieved full text; ICD: Not found in retrieved full text Wang et al. 2024, https://doi.org/10.1186/s12887-024-05088-0 (wang2024identificationofa pages 1-2)

Table: This table summarizes the nomenclature and core identifiers for ATR-X syndrome from the retrieved evidence, including synonyms, OMIM entries, inheritance, prevalence estimates, and publication sources. It also flags identifier systems that were not explicitly available in the retrieved full text.

  • OMIM: ATR-X syndrome is explicitly linked to OMIM 301040 in multiple retrieved sources. (tillotson2023anewmouse pages 1-4, wang2024identificationofa pages 1-2)
  • Related ATRX disorder label in retrieved text: MRXHF1 (X-linked intellectual disability-hypotonic facies syndrome-1) is referenced as an ATRX-related disorder with OMIM 309580. (wang2024identificationofa pages 1-2)
  • Orphanet/ICD/MeSH/MONDO: Not explicitly present in the retrieved full text snippets and therefore not reportable here as evidence-backed codes. (tillotson2023anewmouse pages 1-4, wang2024identificationofa pages 1-2)

1.3 Synonyms / alternative names

Commonly used synonyms in the retrieved literature include: “ATR-X syndrome”, “ATRX syndrome”, “alpha-thalassemia/intellectual disability, X-linked”, and “alpha-thalassemia X-linked intellectual disability”. (tillotson2023anewmouse pages 1-4, wang2024identificationofa pages 1-2)

1.4 Evidence source type

The information synthesized here is derived from (i) aggregated disease-level reviews and cohorts, and (ii) individual case reports with literature review, as well as model organism work (mouse). (wang2024identificationofa pages 1-2, tillotson2023anewmouse pages 1-4, lupu2024pyridostigmineasa pages 2-3)

2. Etiology

2.1 Disease causal factors

Primary cause: germline pathogenic variants in ATRX (Xq21.1), encoding a SNF2-family chromatin remodeling protein with key functional domains (ADD and helicase/ATPase-like domains). (wang2024identificationofa pages 1-2, pang2023thechromatinremodeler pages 1-2)

Variant spectrum and general rule: In ATR-X syndrome, alleles are typically hypomorphic (commonly missense; also small in-frame/other changes), and complete null alleles are not typically seen clinically, consistent with embryonic lethality when ATRX is fully deleted in mouse. (tillotson2023anewmouse pages 1-4, maganaacosta2025atrxfrom pages 13-13)

2.2 Risk factors

For an X-linked Mendelian disorder, the principal “risk factors” are genetic: - Sex (male/hemizygous): male predominance is expected because hemizygous males are typically affected, while female carriers are often less affected, consistent with X-inactivation effects. (yuan2024mutantatrxpathogenesis pages 1-2, maganaacosta2025atrxfrom pages 13-13) - Family history / carrier mother: implied by X-linked inheritance (not quantified in retrieved snippets). (maganaacosta2025atrxfrom pages 13-13)

2.3 Protective factors

No genetic or environmental protective factors were identified in the retrieved full text.

2.4 Gene–environment interactions

No clear gene–environment interaction evidence specific to ATR-X syndrome was found in the retrieved full text.

3. Phenotypes

3.1 Phenotype spectrum and key clinical manifestations

Core features repeatedly described include: - Intellectual disability / developmental delay (universal in many cohorts) - Alpha-thalassemia / HbH features (common but not universal) - Craniofacial dysmorphism - Hypotonia - Urogenital anomalies - Skeletal abnormalities - Gastrointestinal complications (can be severe)

These are summarized across recent reviews and patient-based syntheses. (wang2024identificationofa pages 1-2, tillotson2023anewmouse pages 1-4, yuan2024mutantatrxpathogenesis pages 1-2)

3.2 Phenotype frequencies (recent quantitative data)

Recent cohort-level percentages extracted from a 2024 case + systematic literature synthesis are summarized below.

Phenotype HPO term suggestion Frequency / notes Evidence / source
Intellectual disability HP:0001249 Intellectual disability 100% (reported as 43/43 in the reviewed cohort); described as universal in the summarized ATRX cohort. Wang et al. 2024 review/case synthesis; cohort percentages extracted from text discussing genotype–phenotype relationships (wang2024identificationofa pages 7-8)
Alpha-thalassemia / HbH inclusion HP:0001927 Abnormal hemoglobin; HP:0005523 Hemoglobin H inclusion bodies; HP:0001878 Hemolytic anemia 41.86% overall (18/43) in the summarized cohort; alpha-thalassemia is common but not universal, so absence does not exclude ATR-X syndrome. Wang et al. 2024 phenotype summary (wang2024identificationofa pages 7-8)
Autism / behavioral problems HP:0000729 Autistic behavior; HP:0000708 Behavioral abnormality 44.19% overall (19/43); reported as a recurrent neurobehavioral feature. Wang et al. 2024 phenotype summary (wang2024identificationofa pages 7-8)
Epilepsy HP:0001250 Seizure 23.26% overall (10/43); reported among recurrent neurologic manifestations and noted as more prevalent in frameshift variants than missense variants in the broader review. Wang et al. 2024 phenotype summary and genotype–phenotype discussion (wang2024identificationofa pages 7-8, wang2024identificationofa pages 1-2)
Congenital heart defects HP:0001627 Abnormal heart morphology; HP:0001644 Congenital heart defect 18.60% overall (8/43); reported as an associated but less frequent congenital manifestation. Wang et al. 2024 phenotype summary (wang2024identificationofa pages 7-8)
Mutation-type/domain stratification note Not applicable Full phenotype distributions stratified by mutation type are in Table 1, and genotype–phenotype relationships by affected protein domain are in Table 2 of Wang et al. 2024; these tables were identified from the page images. Table-image extraction identifying Table 1 and Table 2 as the key frequency/genotype–phenotype tables (wang2024identificationofa media 3e3625e3, wang2024identificationofa media bc05e6ce)

Table: This table summarizes key clinical features of ATR-X syndrome with cohort frequencies reported in Wang et al. 2024. It is useful for rapid phenotype curation and notes where the full mutation-type and domain-specific distributions can be found.

Additionally, Table 1 and Table 2 with expanded phenotype frequencies stratified by mutation type and protein domain were identified in the Wang et al. 2024 paper images. (wang2024identificationofa media 3e3625e3, wang2024identificationofa media bc05e6ce)

3.3 Gastrointestinal phenotypes and quality-of-life impact

Gastrointestinal involvement can be clinically dominant and life-threatening in some individuals. A 2024 ATR-X case report and literature review emphasized that ATR-X patients may have gastroesophageal and motility manifestations “most commonly gastroesophageal issues, including chronic gastroesophageal reflux (GER), drooling and constipation.” (lupu2024pyridostigmineasa pages 2-3)

Severe GI complications discussed in this review include intestinal malrotation/volvulus and recurrent bowel volvulus; the review notes such issues can contribute to major morbidity and even mortality. (lupu2024pyridostigmineasa pages 2-3)

3.4 Suggested HPO terms (examples)

Examples are included in the phenotype-frequency artifact and include: - Intellectual disability (HP:0001249) - Seizures (HP:0001250) - Congenital heart defect (HP:0001644) - Autistic behavior (HP:0000729) - HbH inclusion bodies (HP:0005523)

(See | Phenotype | HPO term suggestion | Frequency / notes | Evidence / source | |---|---|---|---| | Intellectual disability | HP:0001249 Intellectual disability | 100% (reported as 43/43 in the reviewed cohort); described as universal in the summarized ATRX cohort. | Wang et al. 2024 review/case synthesis; cohort percentages extracted from text discussing genotype–phenotype relationships (wang2024identificationofa pages 7-8) | | Alpha-thalassemia / HbH inclusion | HP:0001927 Abnormal hemoglobin; HP:0005523 Hemoglobin H inclusion bodies; HP:0001878 Hemolytic anemia | 41.86% overall (18/43) in the summarized cohort; alpha-thalassemia is common but not universal, so absence does not exclude ATR-X syndrome. | Wang et al. 2024 phenotype summary (wang2024identificationofa pages 7-8) | | Autism / behavioral problems | HP:0000729 Autistic behavior; HP:0000708 Behavioral abnormality | 44.19% overall (19/43); reported as a recurrent neurobehavioral feature. | Wang et al. 2024 phenotype summary (wang2024identificationofa pages 7-8) | | Epilepsy | HP:0001250 Seizure | 23.26% overall (10/43); reported among recurrent neurologic manifestations and noted as more prevalent in frameshift variants than missense variants in the broader review. | Wang et al. 2024 phenotype summary and genotype–phenotype discussion (wang2024identificationofa pages 7-8, wang2024identificationofa pages 1-2) | | Congenital heart defects | HP:0001627 Abnormal heart morphology; HP:0001644 Congenital heart defect | 18.60% overall (8/43); reported as an associated but less frequent congenital manifestation. | Wang et al. 2024 phenotype summary (wang2024identificationofa pages 7-8) | | Mutation-type/domain stratification note | Not applicable | Full phenotype distributions stratified by mutation type are in Table 1, and genotype–phenotype relationships by affected protein domain are in Table 2 of Wang et al. 2024; these tables were identified from the page images. | Table-image extraction identifying Table 1 and Table 2 as the key frequency/genotype–phenotype tables (wang2024identificationofa media 3e3625e3, wang2024identificationofa media bc05e6ce) |

Table: This table summarizes key clinical features of ATR-X syndrome with cohort frequencies reported in Wang et al. 2024. It is useful for rapid phenotype curation and notes where the full mutation-type and domain-specific distributions can be found..)

4. Genetic / Molecular Information

4.1 Causal gene

  • ATRX (Xq21.1) is the causal gene for ATR-X syndrome (OMIM 301040). (wang2024identificationofa pages 1-2, tillotson2023anewmouse pages 1-4)

4.2 Pathogenic variant classes and genotype–phenotype notes

A 2024 case report with literature synthesis notes that missense variants are most common overall and that the ADD and helicase-like domains are frequently affected; it also reports mutation-type associations (e.g., frameshift variants showing higher prevalence of epilepsy, congenital heart disease, urogenital, acoustic, and optical defects compared with missense). (wang2024identificationofa pages 1-2)

4.3 Functional consequences and molecular functions (current understanding)

ATRX is described as a chromatin-remodeling ATPase involved in transcriptional regulation, DNA damage repair, and heterochromatin maintenance. (tillotson2023anewmouse pages 1-4)

Mechanistic reviews emphasize ATRX roles in chromatin remodeling and genomic integrity, including cooperating with DAXX to deposit histone variant H3.3 at repetitive regions (e.g., telomeric/pericentromeric heterochromatin). (pang2023thechromatinremodeler pages 1-2, vaisfeld2022phenotypicspectrumand pages 1-2)

4.4 Epigenetic information and episignatures

DNA methylation episignatures are increasingly used as functional biomarkers in neurodevelopmental Mendelian disorders; ATRX has a published episignature that has been independently evaluated and shown high diagnostic performance (see Diagnostics section). (husson2024episignaturesinpractice pages 1-2, trajkova2024dnamethylationanalysis pages 1-2)

5. Environmental Information

No specific environmental toxins, lifestyle factors, or infectious triggers were identified in the retrieved full text as contributing causes for ATR-X syndrome (a genetic disorder).

6. Mechanism / Pathophysiology

6.1 Mechanistic chain (high-level)

ATRX hypomorphic loss → altered recruitment/function of a chromatin remodeling ATPase at heterochromatin and other genomic regions → impaired regulation of transcription, heterochromatin maintenance, and genome stability/replication stress responses → neurodevelopmental defects (ID, microcephaly-like phenotypes), multi-system congenital anomalies, and hematologic dysregulation consistent with alpha-thalassemia in many patients. (tillotson2023anewmouse pages 1-4, tillotson2023anewmouse pages 16-22, pang2023thechromatinremodeler pages 1-2)

6.2 Cell and molecular processes implicated (evidence-backed themes)

  • Chromatin remodeling and transcriptional regulation: ATRX is repeatedly described as a chromatin remodeler/transcriptional regulator. (pang2023thechromatinremodeler pages 1-2, tillotson2023anewmouse pages 1-4)
  • DNA damage/replication stress responses: ATRX is described as involved in DNA damage repair; the patient-mutation knock-in mouse paper also frames ATRX in this functional context. (tillotson2023anewmouse pages 1-4)
  • Heterochromatin maintenance / recruitment via histone marks: the knock-in mouse model highlights disrupted heterochromatin recruitment mediated by ADD-domain binding to H3K9me3, stating “This recruitment is severely disrupted by the R245C mutation.” (tillotson2023anewmouse pages 16-22)

6.3 Suggested ontology terms

  • GO (biological process; examples): chromatin remodeling; DNA repair; regulation of transcription; response to replication stress. (tillotson2023anewmouse pages 1-4, tillotson2023anewmouse pages 16-22)
  • GO (cellular component; examples): heterochromatin; nucleus. (tillotson2023anewmouse pages 16-22)
  • Cell Ontology (CL; examples): neurodevelopmental relevance suggests neural progenitors/neurons; the mouse model includes hippocampal neuron phenotypes (neurite/dendrite changes). (tillotson2023anewmouse pages 13-16, tillotson2023anewmouse pages 10-13)

7. Anatomical Structures Affected

Evidence supports multi-system involvement: - Central nervous system: neurodevelopmental phenotype; mouse knock-in shows reduced brain weight and cerebellar/corpus callosum structural changes. (tillotson2023anewmouse pages 10-13) - Hematopoietic system: alpha-thalassemia is a defining feature for many patients (not universal). (tillotson2023anewmouse pages 1-4, wang2024identificationofa pages 7-8) - Gastrointestinal tract: severe dysmotility/GER/constipation and complications (malrotation/volvulus) reported. (lupu2024pyridostigmineasa pages 2-3) - Urogenital system: genital abnormalities and urogenital defects are part of the typical clinical description. (wang2024identificationofa pages 1-2, tillotson2023anewmouse pages 1-4)

8. Temporal Development

Onset is typically congenital/early childhood consistent with a neurodevelopmental disorder; the knock-in mouse model is framed as developmental rather than degenerative (normal head circumference at birth but later differences in brain size/structure). (tillotson2023anewmouse pages 10-13)

9. Inheritance and Population

9.1 Inheritance

ATR-X syndrome is X-linked and affects “primarily… hemizygous males,” with females often being carriers due to X-inactivation effects. (tillotson2023anewmouse pages 1-4, maganaacosta2025atrxfrom pages 13-13)

9.2 Epidemiology

A 2024 review/case synthesis reports the condition as rare with an estimated prevalence of approximately 1/30,000–1/40,000 male newborns. (wang2024identificationofa pages 1-2)

10. Diagnostics

10.1 Genetic testing (current practice)

WES/NGS is used to identify ATRX variants in suspected cases; one 2024 report diagnosed an ATRX-related phenotype by whole-exome sequencing and applied ACMG criteria for classification. (wang2024identificationofa pages 1-2)

10.2 DNA methylation episignatures (recent developments; 2023–2024 prioritized)

Recent work supports using genome-wide DNA methylation “episignatures” as diagnostic/variant-interpretation tools in neurodevelopmental disorders: - A 2024 independent evaluation of published episignatures reported 100% specificity of the procedure and that the ATRX episignature displayed 100% sensitivity in that dataset. (husson2024episignaturesinpractice pages 1-2) - A 2024 clinical study applying episignatures in neurodevelopmental disorders reported the expected episignature in 53/59 (90%) validation cases and identified an ATRX-associated case via methylation profiling in the test cohort. (trajkova2024dnamethylationanalysis pages 1-2)

10.3 Long-read sequencing integrated genomics + methylation (emerging implementation)

Nanopore long-read sequencing approaches can simultaneously call genetic variants and derive methylation signatures: - A 2024 preprint reported classifier-recognized episignature assignment in 17/20 patients and classification of all healthy controls as controls; the paper also illustrates how episignature and segregation data can support benign interpretation of an ATRX VUS in a complex case. (geysens2024nanoporesequencingbasedepisignature pages 11-14) - A 2025 long-read methylome study included ATR-X syndrome cases and extracted ATR-X-specific long-read DNA methylation signatures as alternatives to array-based signatures. (mizuguchi2025diagnosticutilityof pages 1-2)

A structured diagnostic summary is provided below.

Test modality Purpose Key findings / performance Real-world implementation notes Key references with URL / date
Whole-exome sequencing (WES) / broader NGS Detect germline pathogenic ATRX variants in suspected ATR-X syndrome or related ATRX-associated neurodevelopmental phenotypes WES identified a novel frameshift ATRX variant in a child with ATRX-related disease; the 2024 review/case synthesis notes ATR-X syndrome and MRXHF1 are caused by ATRX pathogenic variants, with missense variants most common overall and ADD/helicase domains frequently affected (wang2024identificationofa pages 1-2) Practical first-line molecular test in rare disease workups; useful when phenotype includes intellectual disability, hypotonia, craniofacial features, genital anomalies, GI disease, seizures, or anemia/alpha-thalassemia; variants are typically classified with ACMG criteria and may require segregation/orthogonal confirmation (wang2024identificationofa pages 1-2) Wang et al., BMC Pediatrics (Oct 2024), https://doi.org/10.1186/s12887-024-05088-0 (wang2024identificationofa pages 1-2)
Whole-genome sequencing (WGS) / structural-variant-capable sequencing Detect SNVs plus structural or intragenic ATRX variants that may be missed or only partially resolved by targeted approaches Long-read WGS-based workflows can simultaneously identify single-nucleotide and structural variants while also deriving methylation data; automated nanopore calling identified 18/19 SNVs in one developmental-disorders cohort, with one low-level mosaic variant requiring manual review (geysens2024nanoporesequencingbasedepisignature pages 11-14) Particularly relevant when prior exome/panel testing is negative, when a CNV/deletion is suspected, or when integrated genomic + epigenomic resolution is needed for interpretation; still emerging rather than universal standard of care for ATRX syndrome (geysens2024nanoporesequencingbasedepisignature pages 11-14, mizuguchi2025diagnosticutilityof pages 1-2) Geysens et al., medRxiv (Apr 2024), https://doi.org/10.1101/2024.04.19.24305959; Mizuguchi et al., Clinical Epigenetics (Feb 2025), https://doi.org/10.1186/s13148-025-01832-0 (geysens2024nanoporesequencingbasedepisignature pages 11-14, mizuguchi2025diagnosticutilityof pages 1-2)
DNA methylation episignature testing (EpiSign / array-based episignature workflow) Functional support for diagnosis and variant interpretation, especially VUS resolution in ATRX-related neurodevelopmental disease In a 97-case NDD series, expected episignatures were observed in 53/59 validation cases (90% overall), and ATRX-associated methylation profiling helped identify an ATRX-related diagnostic case in the test cohort (trajkova2024dnamethylationanalysis pages 1-2) Useful as a second-line functional assay after sequencing when phenotype is compatible but variant classification remains uncertain; can complement genomic findings and improve interpretation of ATRX deletions or uncertain variants (trajkova2024dnamethylationanalysis pages 1-2) Trajkova et al., Human Genetics and Genomics Advances (Jul 2024), https://doi.org/10.1016/j.xhgg.2024.100309 (trajkova2024dnamethylationanalysis pages 1-2)
Independent episignature validation for ATRX signature Assess diagnostic accuracy / readiness for clinical use of published ATRX episignatures Independent validation across ten NDD episignatures reported 100% specificity overall for the procedure, and the ATRX episignature showed 100% sensitivity in that dataset (husson2024episignaturesinpractice pages 1-2) Supports real-world diagnostic confidence for ATRX methylation testing relative to several less robust signatures; authors still caution that broader validation and clear validity boundaries remain important before overgeneralization (husson2024episignaturesinpractice pages 1-2) Husson et al., European Journal of Human Genetics (Oct 2024), https://doi.org/10.1038/s41431-023-01474-x (husson2024episignaturesinpractice pages 1-2)
Nanopore long-read sequencing with integrated episignature detection Simultaneous genetic and epigenetic testing in a single assay In a proof-of-concept developmental-disorders cohort, SVM classifiers recognized an episignature and assigned the correct disease in 17/20 patients, while all healthy controls were classified as controls; the approach also showed how ATRX episignature information can help classify an ATRX variant as benign in a complex case (geysens2024nanoporesequencingbasedepisignature pages 11-14) Consolidates what is often a multi-step workflow (variant detection, CNV/SV analysis, methylation profiling, and in some settings X-inactivation assessment) into one platform; promising for specialized clinical genetics laboratories, but currently best viewed as advanced/early implementation rather than routine everywhere (geysens2024nanoporesequencingbasedepisignature pages 11-14) Geysens et al., medRxiv (Apr 2024), https://doi.org/10.1101/2024.04.19.24305959 (geysens2024nanoporesequencingbasedepisignature pages 11-14)
Nanopore long-read methylome profiling specifically including ATR-X syndrome cases Define long-read DNA methylation signatures unique to ATR-X syndrome and potentially raise diagnostic yield Sequencing of seven ATR-X syndrome cases and 22 controls enabled extraction of ATR-X-specific long-read DNA methylation signatures as alternatives to array-derived episignatures; authors argue simultaneous genetic and epigenetic evaluation may improve discovery and diagnostic yield (mizuguchi2025diagnosticutilityof pages 1-2) Relevant for future integrated diagnostics and for laboratories interested in replacing sequential array + sequencing workflows with one assay; ATRX-specific sensitivity/specificity values were not provided in the retrieved excerpt (mizuguchi2025diagnosticutilityof pages 1-2) Mizuguchi et al., Clinical Epigenetics (Feb 2025), https://doi.org/10.1186/s13148-025-01832-0 (mizuguchi2025diagnosticutilityof pages 1-2)

Table: This table summarizes current diagnostic modalities for ATRX syndrome, spanning standard genomic sequencing and newer DNA methylation episignature approaches. It highlights recent validation and implementation data that are useful for clinical interpretation, especially when variants are uncertain.

11. Outcome / Prognosis

The retrieved evidence is insufficient to provide rigorous survival estimates or life expectancy distributions. However, severe gastrointestinal complications (e.g., malrotation/volvulus) are described as potential causes of severe outcomes including death in some reported contexts, highlighting the need for proactive surveillance and management. (lupu2024pyridostigmineasa pages 2-3)

12. Treatment

12.1 Supportive and symptom-directed management (real-world implementation)

No disease-modifying therapy is established in the retrieved evidence; management is supportive and phenotype-driven.

Gastrointestinal dysmotility: A 2024 case report and review describes pyridostigmine as a potential option and includes a strongly positive single-patient outcome: the patient “was started on oral pyridostigmine… gradually increased… [and] after a year of sustained treatment, his gastrointestinal symptoms fully resolved.” (lupu2024pyridostigmineasa pages 2-3)

The same review summarized safety across pediatric cases: “of the nine patients documented… only one experienced minor side effects (abdominal pain and cramps).” (lupu2024pyridostigmineasa pages 2-3)

12.2 Experimental / emerging therapeutics

A 2025 source summarized exploratory evidence that 5-aminolevulinic acid (5-ALA) may improve cognitive outcomes in a subset of ATR-X patients in a small phase 2 trial (5 participants; 2 responders) and was described as safe/tolerated in that report. (bertocchi2025matrixmetalloproteinase9and pages 57-61)

12.3 MAXO suggestions

A structured treatment-management table with MAXO-style action concepts is provided below.

Intervention Indication/phenotype Dosing Outcome Evidence type MAXO suggestion References
Pyridostigmine ATR-X syndrome with gastrointestinal dysmotility: chronic constipation, abdominal distension, gastroparesis, reflux/feeding difficulty Index ATR-X case: oral 30 mg/day (1.6 mg/kg/day) increased to 60 mg/day (3.2 mg/kg/day) Symptom improvement reported; after 1 year of sustained treatment, gastrointestinal symptoms fully resolved Human clinical case report + literature review MAXO: gastrointestinal motility agent therapy; cholinesterase inhibitor therapy; constipation management Lupu et al. 2024, Front Pediatr, published Dec 2024, https://doi.org/10.3389/fped.2024.1460658 (lupu2024pyridostigmineasa pages 2-3, lupu2024pyridostigmineasa pages 1-2)
Pyridostigmine Pediatric GI dysmotility in ATR-X and related severe dysmotility reports Enteral 0.5 mg/kg twice daily, titrated to 1 mg/kg twice daily Clinical improvement; improvement corroborated by abdominal X-ray in reported pediatric use Human clinical literature summarized in review MAXO: gastrointestinal motility agent therapy Lupu et al. 2024, Front Pediatr, published Dec 2024, https://doi.org/10.3389/fped.2024.1460658 (lupu2024pyridostigmineasa pages 3-4)
Neostigmine followed by pyridostigmine Severe GI dysmotility/intestinal pseudo-obstructive presentations in pediatric literature reviewed with relevance to ATR-X GI management IV neostigmine 0.5 mg in 50 mL NS at 0.5 mg/hr for 10 days, then oral pyridostigmine 180 mg/day or 7 mg/kg/day Reduced hospital length of stay and reduced dependence on parenteral nutrition; no side effects reported in these reviewed cases Human clinical literature summarized in review MAXO: acetylcholinesterase inhibitor therapy; intestinal pseudo-obstruction management Lupu et al. 2024, Front Pediatr, published Dec 2024, https://doi.org/10.3389/fped.2024.1460658 (lupu2024pyridostigmineasa pages 3-4)
Supportive laxative therapy Constipation/dysmotility in ATR-X syndrome Senna, sodium picosulfate, docusate sodium (dose not specified) No definitive effect in reported ATR-X case prior to pyridostigmine escalation Human clinical case report MAXO: laxative therapy; constipation management Lupu et al. 2024, Front Pediatr, published Dec 2024, https://doi.org/10.3389/fped.2024.1460658 (lupu2024pyridostigmineasa pages 3-4)
Surgical/enteral supportive intervention Severe gastroesophageal and nutritional complications in ATR-X syndrome Laparoscopic anterior gastropexy plus button PEG-J (dose not applicable) Reported improvement in nutrition and quality of life in literature summarized by review Human clinical literature summarized in review MAXO: gastrostomy tube placement; gastropexy; enteral nutrition support Lupu et al. 2024, Front Pediatr, published Dec 2024, https://doi.org/10.3389/fped.2024.1460658 (lupu2024pyridostigmineasa pages 2-3)
Pyridostigmine safety summary Pediatric GI dysmotility treatment safety Across nine documented pediatric cases in the review; variable dosing Only one patient had minor adverse events (abdominal pain/cramps); otherwise favorable tolerability Human literature review MAXO: adverse event monitoring during cholinesterase inhibitor therapy Lupu et al. 2024, Front Pediatr, published Dec 2024, https://doi.org/10.3389/fped.2024.1460658 (lupu2024pyridostigmineasa pages 2-3, lupu2024pyridostigmineasa pages 3-4)
5-Aminolevulinic acid (5-ALA) Exploratory treatment for cognitive dysfunction in ATR-X syndrome 24-week phase 2 exploratory trial; exact dose not provided in retrieved evidence 5 patients enrolled; 2/5 showed cognitive improvement; reported as safe and well tolerated; responders had higher blood 5-ALA/PpIX concentrations Early human clinical trial + preclinical rationale MAXO: developmental disability treatment; experimental metabolic therapy; cognitive symptom management Evidence summarized in 2025 review citing phase 2 trial data (bertocchi2025matrixmetalloproteinase9and pages 57-61)

Table: This table summarizes reported management evidence for ATR-X syndrome, emphasizing gastrointestinal dysmotility interventions and the exploratory 5-ALA cognitive trial. It is useful for distinguishing supportive care from early experimental therapy and for mapping interventions to MAXO-style treatment concepts.

13. Prevention

Primary prevention is not applicable for a monogenic X-linked condition in the usual public health sense; prevention focuses on: - Genetic counseling for at-risk families (carrier testing, reproductive counseling) - Prenatal/preimplantation genetic testing where appropriate and locally available

The retrieved texts emphasize that X-linked inheritance and skewed X-inactivation in females complicate presentation and interpretation, reinforcing the need for genetics-guided counseling. (maganaacosta2025atrxfrom pages 13-13, geysens2024nanoporesequencingbasedepisignature pages 11-14)

14. Other Species / Natural Disease

No naturally occurring veterinary ATRX syndrome analogs were identified in the retrieved full text.

15. Model Organisms

15.1 Mouse model (patient-mutation knock-in; key recent development)

A patient-relevant knock-in mouse model was generated carrying the common patient mutation (R246C; modeled as AtrxR245C/y in mice). The authors state it is “the first patient mutation knock-in model of ATR-X syndrome, carrying the most common patient mutation, R246C,” and report that the mice “recapitulate several aspects of the patient disorder, including craniofacial defects, microcephaly and impaired neurological function.” (tillotson2023anewmouse pages 1-4)

A key mechanistic observation is that ADD-domain–mediated recruitment to heterochromatin is disrupted; the paper states: “This recruitment is severely disrupted by the R245C mutation.” (tillotson2023anewmouse pages 16-22)

15.2 Model limitations

The same mouse model did not recapitulate all hallmark human features, including alpha-thalassemia and genital abnormalities, which is important for translational interpretation. (tillotson2023anewmouse pages 13-16)

Notes on evidence gaps vs. template requirements

  • MONDO/Orphanet/ICD/MeSH codes: not available in the retrieved full text; should be imported from the authoritative databases directly (OMIM/Orphanet/MONDO/MeSH/ICD). (tillotson2023anewmouse pages 1-4, wang2024identificationofa pages 1-2)
  • Large natural history cohorts and survival statistics: not identified in the retrieved full text; additional registry/natural history sources would be required.

References

  1. (tillotson2023anewmouse pages 1-4): Rebekah Tillotson, Keqin Yan, Julie Ruston, Taylor de Young, Alex Córdova, Valérie Turcotte- Cardin, Yohan Yee, Christine Taylor, Shagana Visuvanathan, Christian Babbs, Evgueni A Ivakine, John G Sled, Brian J Nieman, David J Picketts, and Monica J Justice. A new mouse model of atr-x syndrome carrying a common patient mutation exhibits neurological and morphological defects. Human Molecular Genetics, 32:2485-2501, Jan 2023. URL: https://doi.org/10.1101/2023.01.25.525394, doi:10.1101/2023.01.25.525394. This article has 9 citations and is from a domain leading peer-reviewed journal.

  2. (yuan2024mutantatrxpathogenesis pages 1-2): Kejia Yuan, Yan Tang, Zexian Ding, Lei Peng, Jinghua Zeng, Huaying Wu, and Qi Yi. Mutant atrx: pathogenesis of atrx syndrome and cancer. Frontiers in Molecular Biosciences, Oct 2024. URL: https://doi.org/10.3389/fmolb.2024.1434398, doi:10.3389/fmolb.2024.1434398. This article has 7 citations.

  3. (pang2023thechromatinremodeler pages 1-2): Ying Pang, Xu Chen, Tongjie Ji, Meng Cheng, Rui Wang, Chunyu Zhang, Min Liu, Jing Zhang, and Chunlong Zhong. The chromatin remodeler atrx: role and mechanism in biology and cancer. Cancers, 15:2228, Apr 2023. URL: https://doi.org/10.3390/cancers15082228, doi:10.3390/cancers15082228. This article has 51 citations.

  4. (wang2024identificationofa pages 1-2): Yishan Wang, Qizhou Ma, Jing Chen, Shaoxin Li, Feifei Zheng, Lei Shi, Xiaoshun Li, Sinan Li, Guanglei Tong, and Hong Li. Identification of a novel frameshift variant of the atrx gene: a case report and review of the genotype–phenotype relationship. BMC Pediatrics, Oct 2024. URL: https://doi.org/10.1186/s12887-024-05088-0, doi:10.1186/s12887-024-05088-0. This article has 4 citations and is from a peer-reviewed journal.

  5. (maganaacosta2025atrxfrom pages 13-13): Mauro Magaña-Acosta and Viviana Valadéz-Graham. atrx : from chromatin remodeling to disease. genesis, Nov 2025. URL: https://doi.org/10.1002/dvg.70031, doi:10.1002/dvg.70031. This article has 1 citations and is from a peer-reviewed journal.

  6. (lupu2024pyridostigmineasa pages 2-3): V. V. Lupu, S. Gürsoy, F. Comisi, C. Soddu, M. Corpino, M. Marica, R. Cacace, T. Foiadelli, and S. Savasta. Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in atr-x syndrome. case report and literature review. Frontiers in Pediatrics, Dec 2024. URL: https://doi.org/10.3389/fped.2024.1460658, doi:10.3389/fped.2024.1460658. This article has 2 citations.

  7. (wang2024identificationofa pages 7-8): Yishan Wang, Qizhou Ma, Jing Chen, Shaoxin Li, Feifei Zheng, Lei Shi, Xiaoshun Li, Sinan Li, Guanglei Tong, and Hong Li. Identification of a novel frameshift variant of the atrx gene: a case report and review of the genotype–phenotype relationship. BMC Pediatrics, Oct 2024. URL: https://doi.org/10.1186/s12887-024-05088-0, doi:10.1186/s12887-024-05088-0. This article has 4 citations and is from a peer-reviewed journal.

  8. (wang2024identificationofa media 3e3625e3): Yishan Wang, Qizhou Ma, Jing Chen, Shaoxin Li, Feifei Zheng, Lei Shi, Xiaoshun Li, Sinan Li, Guanglei Tong, and Hong Li. Identification of a novel frameshift variant of the atrx gene: a case report and review of the genotype–phenotype relationship. BMC Pediatrics, Oct 2024. URL: https://doi.org/10.1186/s12887-024-05088-0, doi:10.1186/s12887-024-05088-0. This article has 4 citations and is from a peer-reviewed journal.

  9. (wang2024identificationofa media bc05e6ce): Yishan Wang, Qizhou Ma, Jing Chen, Shaoxin Li, Feifei Zheng, Lei Shi, Xiaoshun Li, Sinan Li, Guanglei Tong, and Hong Li. Identification of a novel frameshift variant of the atrx gene: a case report and review of the genotype–phenotype relationship. BMC Pediatrics, Oct 2024. URL: https://doi.org/10.1186/s12887-024-05088-0, doi:10.1186/s12887-024-05088-0. This article has 4 citations and is from a peer-reviewed journal.

  10. (vaisfeld2022phenotypicspectrumand pages 1-2): Alessandro Vaisfeld, Sara Taormina, Alessandro Simonati, and Giovanni Neri. Phenotypic spectrum and molecular findings in 17 atr-x syndrome italian patients: some new insights. Genes, 13:1792, Oct 2022. URL: https://doi.org/10.3390/genes13101792, doi:10.3390/genes13101792. This article has 6 citations.

  11. (husson2024episignaturesinpractice pages 1-2): Thomas Husson, François Lecoquierre, Gaël Nicolas, Anne-Claire Richard, Alexandra Afenjar, Séverine AUDEBERT-BELLANGER, Catherine Badens, Frédéric Bilan, Varoona Bizaoui, Anne Boland, Marie-Noelle Bonnet-Dupeyron, Elise Brischoux-Boucher, Céline Bonnet, Marie Bournez, Odile Boute, Perrine Brunelle, Roseline Caumes, Perrine Charles, Nicolas Chassaing, Nicolas Chatron, Benjamin Cogné, Estelle Colin, Valérie Cormier-Daire, Rodolphe Dard, Benjamin Dauriat, Julian Delanne, Jean-François Deleuze, Florence Demurger, Anne-Sophie Denommé-Pichon, Christel Depienne, Anne Dieux Coeslier, Christèle Dubourg, Patrick Edery, salima EL CHEHADEH, Laurence Faivre, Mélanie FRADIN, Aurore Garde, David Geneviève, Brigitte Gilbert-Dussardier, Cyril Goizet, Alice Goldenberg, Evan Gouy, Anne-Marie Guerrot, Anne Guimier, Ines HARZALLAH, Delphine Héron, Bertrand Isidor, Xavier Le Guillou Horn, Boris Keren, Alma Kuechler, Elodie Lacaze, Alinoë Lavillaureix, Daphné Lehalle, Gaetan Lesca, James Lespinasse, Jonathan Levy, Stanislas Lyonnet, Godelieve Morel, Nolwenn Jean Marçais, Sandrine Marlin, Luisa Marsili, Cyril Mignot, Sophie Nambot, Mathilde Nizon, Robert Olaso, Laurent PASQUIER, Laurine Perrin, Florence Petit, Amélie Piton, Fabienne Prieur, Audrey Putoux, Marc Planes, Sylvie Odent, Chloé Quelin, Sylvia Quemener, Mélanie Rama, Marlène RIO, Massimiliano Rossi, Elise Schaefer, Sophie Rondeau, Pascale SAUGIER-VEBER, Thomas Smol, Sabine Sigaudy, Renaud TOURAINE, Frédéric Tran-Mau-Them, Aurélien Trimouille, Clémence Vanlerberghe, Valérie Vantalon, Gabriella Vera, Marie Vincent, Alban Ziegler, Olivier Guillin, Dominique Campion, and Camille Charbonnier. Episignatures in practice: independent evaluation of published episignatures for the molecular diagnostics of ten neurodevelopmental disorders. European Journal of Human Genetics, 32:190-199, Oct 2024. URL: https://doi.org/10.1038/s41431-023-01474-x, doi:10.1038/s41431-023-01474-x. This article has 38 citations and is from a domain leading peer-reviewed journal.

  12. (trajkova2024dnamethylationanalysis pages 1-2): Slavica Trajkova, Jennifer Kerkhof, Matteo Rossi Sebastiano, Lisa Pavinato, Enza Ferrero, Chiara Giovenino, Diana Carli, Eleonora Di Gregorio, Roberta Marinoni, Giorgia Mandrile, Flavia Palermo, Silvia Carestiato, Simona Cardaropoli, Verdiana Pullano, Antonina Rinninella, Elisa Giorgio, Tommaso Pippucci, Paola Dimartino, Jessica Rzasa, Kathleen Rooney, Haley McConkey, Aleksandar Petlichkovski, Barbara Pasini, Elena Sukarova-Angelovska, Christopher M. Campbell, Kay Metcalfe, Sarah Jenkinson, Siddharth Banka, Alessandro Mussa, Giovanni Battista Ferrero, Bekim Sadikovic, and Alfredo Brusco. Dna methylation analysis in patients with neurodevelopmental disorders improves variant interpretation and reveals complexity. Human Genetics and Genomics Advances, 5:100309, Jul 2024. URL: https://doi.org/10.1016/j.xhgg.2024.100309, doi:10.1016/j.xhgg.2024.100309. This article has 18 citations and is from a peer-reviewed journal.

  13. (tillotson2023anewmouse pages 16-22): Rebekah Tillotson, Keqin Yan, Julie Ruston, Taylor de Young, Alex Córdova, Valérie Turcotte- Cardin, Yohan Yee, Christine Taylor, Shagana Visuvanathan, Christian Babbs, Evgueni A Ivakine, John G Sled, Brian J Nieman, David J Picketts, and Monica J Justice. A new mouse model of atr-x syndrome carrying a common patient mutation exhibits neurological and morphological defects. Human Molecular Genetics, 32:2485-2501, Jan 2023. URL: https://doi.org/10.1101/2023.01.25.525394, doi:10.1101/2023.01.25.525394. This article has 9 citations and is from a domain leading peer-reviewed journal.

  14. (tillotson2023anewmouse pages 13-16): Rebekah Tillotson, Keqin Yan, Julie Ruston, Taylor de Young, Alex Córdova, Valérie Turcotte- Cardin, Yohan Yee, Christine Taylor, Shagana Visuvanathan, Christian Babbs, Evgueni A Ivakine, John G Sled, Brian J Nieman, David J Picketts, and Monica J Justice. A new mouse model of atr-x syndrome carrying a common patient mutation exhibits neurological and morphological defects. Human Molecular Genetics, 32:2485-2501, Jan 2023. URL: https://doi.org/10.1101/2023.01.25.525394, doi:10.1101/2023.01.25.525394. This article has 9 citations and is from a domain leading peer-reviewed journal.

  15. (tillotson2023anewmouse pages 10-13): Rebekah Tillotson, Keqin Yan, Julie Ruston, Taylor de Young, Alex Córdova, Valérie Turcotte- Cardin, Yohan Yee, Christine Taylor, Shagana Visuvanathan, Christian Babbs, Evgueni A Ivakine, John G Sled, Brian J Nieman, David J Picketts, and Monica J Justice. A new mouse model of atr-x syndrome carrying a common patient mutation exhibits neurological and morphological defects. Human Molecular Genetics, 32:2485-2501, Jan 2023. URL: https://doi.org/10.1101/2023.01.25.525394, doi:10.1101/2023.01.25.525394. This article has 9 citations and is from a domain leading peer-reviewed journal.

  16. (geysens2024nanoporesequencingbasedepisignature pages 11-14): Mathilde Geysens, Benjamin Huremagic, Erika Souche, Jeroen Breckpot, Koenraad Devriendt, Hilde Peeters, Griet Van Buggenhout, Hilde Van Esch, Kris Van Den Bogaert, and Joris Robert Vermeesch. Nanopore sequencing-based episignature detection. MedRxiv, Apr 2024. URL: https://doi.org/10.1101/2024.04.19.24305959, doi:10.1101/2024.04.19.24305959. This article has 3 citations.

  17. (mizuguchi2025diagnosticutilityof pages 1-2): Takeshi Mizuguchi, Nobuhiko Okamoto, Taiki Hara, Naoto Nishimura, Masamune Sakamoto, Li Fu, Yuri Uchiyama, Naomi Tsuchida, Kohei Hamanaka, Eriko Koshimizu, Atsushi Fujita, Kazuharu Misawa, Kazuhiko Nakabayashi, Satoko Miyatake, and Naomichi Matsumoto. Diagnostic utility of single-locus dna methylation mark in sotos syndrome developed by nanopore sequencing-based episignature. Clinical Epigenetics, Feb 2025. URL: https://doi.org/10.1186/s13148-025-01832-0, doi:10.1186/s13148-025-01832-0. This article has 1 citations and is from a peer-reviewed journal.

  18. (bertocchi2025matrixmetalloproteinase9and pages 57-61): I Bertocchi, F Tempia, E Hoxha, and A Oberto. Matrix metalloproteinase-9 and perineuronal nets as new therapeutic targets for fragile x syndrome (fxs). Unknown journal, 2025.

  19. (lupu2024pyridostigmineasa pages 1-2): V. V. Lupu, S. Gürsoy, F. Comisi, C. Soddu, M. Corpino, M. Marica, R. Cacace, T. Foiadelli, and S. Savasta. Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in atr-x syndrome. case report and literature review. Frontiers in Pediatrics, Dec 2024. URL: https://doi.org/10.3389/fped.2024.1460658, doi:10.3389/fped.2024.1460658. This article has 2 citations.

  20. (lupu2024pyridostigmineasa pages 3-4): V. V. Lupu, S. Gürsoy, F. Comisi, C. Soddu, M. Corpino, M. Marica, R. Cacace, T. Foiadelli, and S. Savasta. Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in atr-x syndrome. case report and literature review. Frontiers in Pediatrics, Dec 2024. URL: https://doi.org/10.3389/fped.2024.1460658, doi:10.3389/fped.2024.1460658. This article has 2 citations.

Artifacts